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Peripheral arterial disease (PAD), which affects approximately 10 million 
Americans, is characterized by atherosclerosis of the non-coronary arteries.  PAD 
produces a progressive accumulation of ischemic injury to the limbs that is reflected in a 
gradual worsening in the myofiber morphology and oxidative damage in the 
gastrocnemius muscle.  In this study, we evaluated the hypothesis that quantitative 
morphological and biochemical parameters of gastrocnemius myofibers change in a 
consistent manner during the progression of PAD, provide an objective grading of muscle 
degeneration in the ischemic limb, and correlate to clinical stage of PAD.  Myofiber 
morphometrics were determined precisely with mathematical equations that incorporated 
multiple, objectively defined parameters including fiber density, roundness, minor and 
major axes, and solidity.  Oxidatively altered proteins (hydrazide-reactive carbonyls) 
labeled with mechanisms-based molecular biomarkers were imaged with quantitative 
fluorescence microscopy and were used to measure oxidative damage in the muscle.  A 
discriminant model was developed based on morphometric and oxidative stress 
parameters that accurately identified control (85.7% accuracy), claudicating (78.9% 
accuracy), and critical limb ischemia (85.0% accuracy) patients, with an overall 
  
classification accuracy of 83.3% using a cross-validation procedure.  We have established 
that there are consistent and quantifiable changes in myofiber morphology and 
biochemistry that reflect the progression of PAD muscle degeneration and offer the 
possibility of an objective index for grading severity of disease within clinical 
classifications, i.e., Fontaine Stages.   
Further, we evaluated the use of Raman scattering spectral biomarkers to 
characterize altered muscle biochemistry in PAD patients and correlate patient blood 
flow (ABI) with key Raman spectral bands.  A partial least squares regression model, 
based on the Raman spectra, was able to predict patient ABIs with a correlation 
coefficient of 0.85 using a full cross-validation.  When using the first three partial least 
squares factor scores in combination with linear discriminant analysis, the discriminant 
model was able to correctly classify control, claudicating, and critical limb ischemia 
patients with 100% accuracy, using a full cross-validation procedure.  In this study, we 
have demonstrated that Raman spectroscopy can be a powerful bioanalytical tool that is 
capable of detecting and correlating biochemical composition with patient ABIs and 
discriminating PAD clinical diagnosis.    
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CHAPTER 1 : INTRODUCTION 
1.1 BACKGROUND OF PERIPHERAL ARTERIAL DISEASE (PAD) 
Peripheral arterial disease (PAD), also known as peripheral vascular disease 
(PVD) or peripheral artery occlusive disease (PAOD), is a vascular disease characterized 
by atherosclerosis and stenosis (abnormal narrowing) of the non-coronary arteries (Hirsch 
et al., 2006).  PAD is a slowly progressive disease that develops over many years and 
often goes unnoticed (Norgren et al., 2007).  In the early stages of PAD most people have 
no symptoms, but have an atherosclerotic condition that is the underlying problem with 
PAD (Feinglass et al., 1999; Allison et al., 2007).  Atherosclerosis is a hardening of the 
arteries which occurs when fatty deposits, cholesterol, and plaque buildup on the inner 
linings of the arterial walls (Bonow et al., 2011).  This atherosclerotic condition causes 
vascular channels to harden, narrow, and lose elasticity resulting in reduced blood flow to 
the limbs generally expressing symptoms in the lower extremities.  Although PAD affects 
a large range of arterial beds, most occlusions occur in the arteries of the legs, pelvis, and 
abdominal aorta (Hirsch et al., 2006).  Ambulatory pain caused by inadequate blood flow 
and muscle damage in the lower extremities is known as claudication.  The physical 
manifestations of PAD are outward presentations of a myopathy secondary to the 
vascular disease.  Claudication is one of the first manifestations of PAD and is an early 
indicator of muscle disease, in which myofibers begin to deteriorate due to altering 
metabolic processes resulting in changes of muscle morphology.  Other advanced clinical 
manifestations of PAD are pain while at rest, non-healing foot ulcers, and gangrene. 
2 
 
1.2 SIGNIFICANCE OF PAD 
It is estimated that PAD affects approximately 8 – 10 million Americans (Norgren 
et al., 2007).  This condition becomes more common as one gets older and the number of 
affected Americans is expected to increase with an increase of the elderly population.  It 
is estimated that approximately 12 to 20 percent of the population may have PAD by the 
age of 65 (Ostchega et al., 2007).  The seriousness of this disease is compounded with a 
four to five times higher risk of having a heart attack or stroke.   
In general, vascular diseases encompass any condition which negatively affects 
the arteries, veins, and lymph vessels, with the most common underlying problem being 
atherosclerosis.  It is estimated that approximately 82,600,000 American adults have at 
least one or more types of vascular disease (Roger et al., 2011).  Other prevalent forms of 
vascular disease are cerebrovascular disease (CVD) and coronary heart disease (CHD).  
Among the vascular diseases, PAD is the third most prevalent.   Patients presenting with 
PAD symptoms are also likely to have widespread accumulation of fatty deposits in the 
arteries and have coexisting forms of vascular disease (Figure 1.1) (Hirsch et al., 2006; 
Bhatt et al., 2006; Suominen, 2008).  Due to the systematic buildup of atherosclerosis 
over many years, patients with PAD commonly have arterial occlusions in other vascular 
locations such as the brain and heart.  Moreover, data from the Reduction of 
Atherothrombosis for Continued Health (REACH) Registry, a large international registry 
with patient data for symptomatic atherothrombosis with CHD, CVD, and PAD, reports 
that patients with PAD have highter rates of polyvascular disease when compared to 
patients with CAD or CHD (Bhatt et al., 2006).  
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Figure 1.1.  Coexistence and distribution of three most prevalent forms of vascular 
disease.  Coronary heart disease (CHD), cerebrovascular disease (CVD), and peripheral 
arterial disease (PAD). Modified from: (Bhatt et al., 2006)   
  
1.2.1 Economic impact 
Prevalence of PAD produces a considerable public health burden in terms of 
economic cost as well as decreased quality of life.  PAD is becoming increasingly 
recognized as a major cardiovascular public health burden due to its increased risk of 
polyvascular disease and the increased probability of patients having a major 
cardiovascular ischemic event (Bhatt et al., 2006).  It is estimated that approximately 
260,000 revascularization procedures are performed each year in the United States 
(Feinglass et al., 1999).  Additionally, in the 1990’s it was reported that approximately 
100,000 amputations occur each year in the U.S. (Tunis et al., 1991).  This number 
increased to 160,000 amputations each year in the United States, in 2004 (The Sage 
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Group, 2004).  Among these patients that undergo limb amputation, there is a 60% 
chance of surviving the next 2 years of life.  Based on a 2004 U.S. census, the total 
estimated annual cost of PAD, associated with vascular-related procedures and 
hospitalizations, was in excess of $21 billion dollars (Mahoney et al., 2008).  According 
to the Sage Group, this number could be reduced by $2.9 billion if the number of 
amputations were reduced by 25% (The Sage Group, 2004).  Amputation is considered to 
be a medical failure to treat the disease and controlling the health care costs of PAD 
represents a major challenge.  
1.2.2 Severity of PAD and Survival 
As PAD severity increases the risk of limb loss and mortality increases as well.  It 
is estimated that once a patient has been diagnosed with critical limb ischemia 20% of 
those will die within the first year (Figure 1.2) and another 35% will require amputation 
(Norgren et al., 2007; The Sage Group, 2004).  Limb loss is closely linked to a significant 
reduction in quality of living and many patients will require mobility assistance for the 
rest of their lives, which can be a difficult and emotional issue.  Major amputations are 
not only undesirable disfiguring operations, but also carry high perioperative mortality 
and morbidity rates.  Perioperative mortality rates during amputation range from 4%-30% 
and have morbidity rates from 20%-37% (The Sage Group, 2004).  Furthermore, it is 
estimated that only 40% of patients that have below-the-knee operations and only 20% 
that undergo above-the-knee amputations ever return to full mobility (The Sage Group, 
2004).  
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Figure 1.2.  Mortality of patients presenting with peripheral arterial disease. IC – 
intermittent claudication; CLI – critical limb ischemia.  Courtesy of: (Norgren et al., 
2007)  
 
1.3 STATEMENT OF THE PROBLEM 
Peripheral arterial disease (PAD) is an aging-related disease affecting more than 
10 million patients in the United States (Norgren et al., 2007; Hiatt et al., 1995).  PAD 
produces a considerable public health burden (Mahoney et al., 2008; Mahoney et al., 
2010) and the ability to profile the biochemical alterations and characterize the extent of 
muscle damage due to the disease would provide physicians with objective measures to 
diagnose, monitor muscle degeneration, and develop patient-specific treatments.  The 
fundamental problem in PAD patients is the presence of atherosclerotic blockages in the 
arteries supplying blood to their legs.  The pathophysiology of PAD involves changes 
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occurring on multiple levels including, reduced blood flow, altered metabolic processes, 
and muscle degeneration (Stewart et al., 2002).  Repeated cycles of ischemia followed by 
reperfusion, occurring with basic daily activities, initiates a myopathy causing muscle 
degeneration and can produce foot ulcers, gangrene, and eventual limb loss (Hedberg et 
al., 1988a; Pipinos et al., 2008; Pipinos et al., 2008b).  There is a fundamental gap in 
monitoring muscle degeneration progression and regression before and after vascular 
reperfusion surgeries.  Limb hemodynamics, such as Ankle Brachial Index (ABI) is the 
current gold standard in diagnosing and monitoring treatment interventions of PAD.  
Other advanced methods such as, ultrasonography, venous plethysmography, 
angiography (x-ray) or (MRA), have been employed to characterize PAD based on 
monitoring blood flow.  However, all these methods have limitations in monitoring 
progression and regression of PAD because there is a need to measure more than just 
blood flow; there is a need to measure muscle degeneration as well.  The contribution of 
this dissertation is to develop and evaluate direct measurements of biochemical 
alterations and muscle degeneration in PAD muscle.  This contribution is significant 
because it represents a next step in PAD muscle degeneration research, which is expected 
to advance the field in directing therapeutic intervention and monitoring clinical 
treatment interventions of PAD. 
Optimal diagnosis and treatment monitoring of PAD requires objective, specific, 
and measureable quantification of the extent and type of damage present in a PAD 
patient.  This study proposes the use of morphometric determinants, biochemical 
(mechanisms-based biomarker expressions), and spectral (Raman spectroscopic 
parameters) of myofibers, in needle biopsies of the gastrocnemius, as tools 
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complimentary to traditional diagnosis/monitoring procedures, providing objective 
criteria for therapeutic interventions. 
 
1.4 OBJECTIVES 
In this study, we will evaluate the hypothesis that morphometric determinants, 
biochemical (mechanisms-based biomarker expressions), and spectral (Raman scattering) 
parameters of myofibers, in needle biopsies of the gastrocnemius, discriminate PAD 
patients from controls and quantify disease severity, providing objective criteria for 
therapeutic interventions. 
1.4.1 Specific objectives of this research are to: 
i. Develop quantifiable morphometric parameters of PAD and control 
myofibers that objectively discriminate stages of PAD and model the 
biological phenomenon, with advanced mathematical modeling.   
ii. Quantify oxidatively altered proteins (hydrazide-reactive carbonyls) with 
mechanisms-based molecular biomarkers and mathematically model disease 
progression based on a combination of morphometrics and oxidative damage.  
iii. Identify Raman scattering spectral signatures of the muscle biochemistry 
unique to PAD patients and correlate patient blood flow (ABI) with 
identified Raman spectral signatures.  
The development, evaluation, and validation of advanced mathematical models of 
the myopathy of PAD will lead to:  
a. Development of patient-specific treatment plans by providing information that 
reflects underlying pathophysiology (levels of injury in the muscle), which allows 
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the development of individualized therapy, replacing the less effective “one size 
fits all” approach;  
b. Improved monitoring of established (in daily clinical practices) and novel (in 
clinical trials) treatment strategies. 
1.5 DISSERTATION ORGANIZATION 
Chapter 2 presents a literature review of key concepts related to this dissertation 
project, including a background of PAD, risk factors, and diagnostic methods.  The 
chapter will include, in addition, a review of muscle physiology, bioenergetics, and 
vibrational spectroscopy.  
There are three main phases to this project.  Objective I, covered in Chapter 3, deals 
the development of a grading index to grade muscle deterioration of PAD patients based 
on morphometric parameters of muscle fibers.  Objective II, covered in Chapter 4, 
provides a mathematical model to characterize PAD disease progression based on a 
combination of morphometrics and oxidative damage of the myofibers.  Objective III, 
covered in Chapter 5, demonstrates the ability to capture a molecular profile of PAD 
muscle using vibrational spectroscopy.  Following these chapters a summary and 
suggestions for future research are provided. 
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CHAPTER 2 : LITERATURE REVIEW 
2.1 DIAGNOSIS & CLINICAL MANIFESTATIONS 
2.1.1 Risk Factors 
Since PAD is a manifestation of atherosclerosis, the underlying problem in vascular 
diseases, classic risk factors for developing atherosclerosis are also risk factors for 
developing PAD.  Risk factors that increase likelihood of developing lower extremity 
PAD include male sex, age per 10 years, cigarette smoking, diabetes, dyslipidemia, 
hypertension, race, C-reactive protein, renal insufficiency, and hyperhomocysteinemia 
(Hirsch et al., 2006; Norgren et al., 2007).  Figure 2.1 presents the approximate odds 
ratios for these risk factors.  Several investigations have reported that most of these risk 
factors appear to be independent of each other and their effects become additive (Norgren 
et al., 2007).   
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Figure 2.1.  Range of odds ratios of risk factors for developing symptomatic peripheral 
arterial disease.  Modified from: (Norgren et al., 2007)  
2.1.2 Smoking 
Among these etiological risk factors for PAD, cigarette smoking is one of the most 
important and can increase the risk of developing PAD by up to three times (Figure 2.2) 
(Norgren et al., 2007; Criqui et al., 1997).  In other larger investigations even higher 
levels of risk, as much as 2 to 6 fold increases, for developing PAD and increasing 
severity of PAD, are attributed to smoking (Kannel and McGee, 1985; Smith et al., 1990; 
Bowlin et al., 1994).  Approximately 80% of patients with lower extremity PAD were 
found to be either current smokers or were smokers previously (Smith et al., 1990; Meijer 
et al., 1998).  The number of cigarette packs smoked per year has a direct correlation with 
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an increased risk of limb amputation, increased disease severity, and mortality (Norgren 
et al., 2007). 
 
Figure 2.2.  Approximate magnitude of increase in risk of developing PAD based on 
identified risk factors.  Modified from: (Norgren et al., 2007) 
 
2.1.3 Diabetes mellitus 
Similarly, patients with diabetes mellitus have an exceptionally higher risk of 
developing PAD.  The duration and severity of diabetes has been found to be 
proportional to the risk of developing PAD (Beks et al., 1995).  Furthermore, diabetic 
patients that develop PAD, also have a 7 to 10 fold increase in likely hood to undergo a 
major amputation (Most and Sinnock, 1983).  Progression of PAD severity is also more 
aggressive in patients that have diabetes.  Other studies have also shown that patients that 
do not have diabetes, but have insulin resistance have a 40% to 50% increase in risk for 
developing PAD (Muntner et al., 2005).  
Diabetic x4 
Smoker x3 
ABPI <0.5 x2.5 
Age >65 x2 
Risk of 
developing 
PAD 
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2.1.4 Age & Gender 
Prevalence of PAD increases as one gets older.  It is estimated that 12-15% of the 
population above the age 65 has PAD (Ostchega et al., 2007) and the number of affected 
Americans is expected to increase with an increase of the elderly population (Feinglass et 
al., 1999).  In the National Health and Nutrition Examination Survey 1999-2004, data 
was collected from 3,947 men and women above the age of 60 who had lower extremity 
PAD.  In that study they observed that PAD prevalence was 7% among those who were 
60-69 years of age, 12.5%, and 23.2% prevalence for patients between 70 to 79 and 80 to 
older, respectively (Ostchega et al., 2007).  As a whole, PAD generally increases steadily 
beyond the age of 50 with increases in the range of 3% to 18% and further increasing to 
25% and 30% beyond the age 75 (Ostchega et al., 2007; Meijer et al., 1998).   
In addition to age, gender has been shown to play a role in PAD prevalence, as 
well.  In the Framingham Heart Study, a large cohort of 2336 men and 2873 women 
between the ages 28 and 62 were examined for PAD prevalence.  The investigators 
observed that PAD was twice as prevalent in men when compared to women (Kannel et 
al., 1970).  Figure 2.3 displays the results of a study (Criqui et al., 1985) that shows both 
PAD prevalence increasing with age and that men have a higher occurrence of PAD than 
women.  
17 
 
 
Figure 2.3.  PAD prevalence increases as one gets older.  PAD is more common among 
men.  Courtesy of (Criqui et al., 1985).  
 
2.1.5 Race 
Some investigations have displayed evidence that suggests that ethnic background 
plays a role in the evolution of symptomatic peripheral arterial disease as well (Kullo et 
al., 2003). A study performed by The National Health and Nutrition Examination Survey 
in the United States reported that PAD was more common in non-Hispanic Blacks with a 
7.8% prevalence compared to a 4.4% prevalence among Whites.  The Genetic 
Epidemiology Network of Ateriopathy (GENOA) study reported that this difference in 
PAD prevalence between races was not explained by differences in the classical risk 
factors and confirmed that there is indeed an effect due to race.  In a large study, 
conducted by Selvin et al. (2004),  2,174 patients of ages 40 years and over,  similar 
results were reported indicating that blacks are disproportionately affected by PAD 
(Selvin and Erlinger, 2004).  In addition to African-American individuals, the National 
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Health and Nutrition Examination Survey also showed that Mexican-American women 
reported higher prevalence of PAD when compared to non-Hispanic white men and 
women (Ostchega et al., 2007).  
2.1.6 Ankle Brachial Index (ABI) 
Diagnosis of PAD depends upon a physical examination that focuses on the 
circulatory system of the patient.  The ankle-brachial index (ABI) has become the clinical 
hallmark measurement to assess the vascular haemodynamics for the initial diagnosis of 
PAD.  An ABI measurement is performed by measuring the systolic blood pressure of the 
ankle, with a 10−12 cm sphygmomanometer cuff and normalizing it with the systolic 
blood pressure of the brachial artery.  Figure 2.4 displays values of the ankle-brachial 
index and the corresponding diagnosis.  If a patient presents with an ABI of less than 0.90 
they will be diagnosed with PAD.  Patients presenting with ABI’s of 0.41 – 0.90 are 
considered to have moderate PAD, while patients presenting with ABI’s less than 0.40 
are considered to have severe PAD.  In a healthy patient the normal resting ABI will be 
approximately equal to one, meaning that the systolic blood pressure in the brachial 
artery of the arm is similar to that of the systolic blood pressure of the ankle.  An ABI 
value around one indicates that there are no significant blockages or narrowing in the 
arteries of the lower extremities.  ABI’s greater than 1.3 are indicative of non-
compressible or calcified arteries and patients presenting with high ABI’s should undergo 
further vascular circulation assessment.  
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Figure 2.4.  Ankle brachial index (ABI): Modified from: (Norgren et al., 2007) 
 
 The Ankle-Brachial index is generally accepted as an inexpensive, noninvasive, 
rapid method of screening, diagnosing, and managing PAD.  Although many clinicians 
report that the ABI procedure in not reimbursable through insurances and is therefore 
often not performed as a screening or prevention measure.  In the clinical setting, ABI’s 
can be acquired within 15 minutes and most clinicians believe that it is a useful tool in 
the diagnosis and management of PAD.  Literature reports indicate that ABI is able to 
detect a stenosis of 50% reduction in the artery lumen with sensitivity (true positive rate) 
of 79% and specificity (true negative rate) of 96% (Lijmer et al., 1996).  These numbers 
suggest ABI is a sufficient tool to diagnose PAD.  An additional evaluation of 35 patients 
with claudication measured 7 different times demonstrated that the ABI’s can be 
Left-arm  
systolic pressure 
Left-ankle 
 systolic pressure 
Right-arm  
systolic pressure 
Right-ankle 
 systolic pressure 
Ankle Brachial Index 
>1.3  Non-compressible 
1.00 − 1.29  Normal 
0.91 – 0.99 Borderline PAD 
0.41 – 0.90  Mild-to-moderate PAD 
0.00 – 0.40 Severe PAD 
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consistent as well, with a standard deviation of 0.07 (Baker and Dix, 1981).  Other 
studies reported similar variances and overall the ABI measurement is expected to have a 
reproducibility of 0.10, with most of the variation coming from the measurement method 
and not due to the differences between observers (Carter, 1969; Strandness et al., 2002; 
Yao, 1970).    
In addition to PAD diagnosis, ABI is also a good predictor of survival rates and 
future cardiovascular events.  In a large study of nearly 2000 claudicating patients it was 
shown that patients with an ABI <0.50 had twice the mortality rate when compared to the 
patients with ABI>0.50 (Dormandy and Murray, 1991).  This study demonstrated that 
there is a strong correlation between ABI and mortality.  Other investigations observed 
that there is an inverse relationship between increasing ABI and the odds of a patient 
having a major cardiovascular event.  As the ABI’s decrease the risk of myocardial 
infarction, stroke, or death significantly increases (Mehler et al., 2003).  Figure 2.5 
displays this inverse relationship between ABI and the odds of a major cardiovascular 
event.  
21 
 
 
Figure 2.5 There is an inverse relationship between ABI and the odds of having a major 
cardiovascular event.  The lower the ABI the higher the odds of having a myocardial 
infarction, stroke, or death.  Courtisy of: (Mehler et al., 2003) 
 
In another study, McLafferty et al., (1997) investigated the use of ABI to monitor 
the progression of lower extremity PAD after revascularization procedures (McLafferty 
et al., 1997).  In that study, the criterion used to judge PAD progression was a 0.15 
change in the ABI as well as other clinical measures acquired 3 years post operation.  
They reported that ABI was able to monitor PAD progression with a sensitivity of 41%, a 
specificity of 84%, and an overall accuracy of 68%.  Based on these numbers ABI’s may 
not be sufficient to monitor progression of PAD.  Although, previously mentioned studies 
suggest that ABI is a good diagnostic measure of PAD, the accuracy rates reported by 
McLafferty et al. suggest that ABI may not be suitable for monitoring progression of 
PAD. 
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Despite the usefulness of ABI to predict survival and diagnosis of PAD, other 
studies highlight the limitations of the ABI.  Duerschmied et al. (2010) argue that non-
invasive tests such as the ABI lack reliability, especially in patients with local edema or 
incompressible arteries (Duerschmied et al., 2010).  In their study they suggest using 
contrast ultrasound perfusion imaging of the calf muscle as a viable alternative.  They 
claim that contrast ultrasound could help in monitoring the limb hemodynamics even 
when patients have edema or incompressible arteries.  Another study suggests that other 
supplementary methods of diagnosis should be considered especially when there is 
clinical suspicion of PAD with an ABI close to 0.90 (Nam Su Chung et al., 2010).  Stein 
et al. (2006) demonstrated that the sensitivity for detecting PAD with a resting ABI is 
only high when there is a high grade of stenosis (>50% narrowing of the artery) and that 
some patients who have PAD can present with normal ABI’s, but after limb exercise they 
present with a decrease in the ABI.  In their study they reported that even patients with 
rest pain and/or foot ulcerations had normal ABI’s 51% and 44% of the time.  Within this 
group of PAD patients, with normal ABI’s, exercise testing followed by ABI disclosed 
abnormalities in the blood flow that are consistent with PAD.  Therefore, the ABI can be 
enhanced by combining ABI with exercise testing (Stein et al., 2006).   
Kramer (2007) raised the concern that ABI’s and other limb hemodynamic 
measurements only measure the burden of plaque buildup on the circulatory system and 
do not measure the end-organ effects of the plaque buildup (Kramer, 2007).  Although 
one can speculate that there will be a correlation between the end-organ damage and the 
ABI, this is a problem when patients present with normal ABI s, but have PAD.  
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Knowing the plaque buildup is not enough, there is also a need to measure the damage 
caused by the abnormal blood flow and the overall effect on limb function.  These types 
of arguments were raised when clinicians and researchers noticed that even after 
revascularization procedures patients continued to have a decline in walking parameters 
(Regensteiner et al., 1993; Gardner and Killewich, 2001).  The continued decline of limb 
functional parameters, such as slower walking velocity, poorer standing balance, slower 
time to arise from a seated position, suggests that there are continued end-organ effects 
on the limbs even after revascularization.  This suggests the need to measure more than 
just blood flow.  Overall, the ABI measurement is effective in the initial diagnosis of 
PAD, but has limitations in providing information about the state of muscle degeneration.  
2.1.7 Claudication & Critical Limb Ischemia 
Ambulatory pain caused by inadequate blood flow to the muscles in the lower 
extremities is known as claudication.  Claudication is medically defined as fatigue, 
discomfort, or pain that is induced in the limbs during exercise (Hirsch et al., 2006).  
Although patients can experience leg pain for many other reasons than PAD, the key 
indicator of PAD is that the pain is associated with exercise.  The exercise induced 
ischemic conditions cause a mismatch of oxygen supply and increased demand within the 
muscle during exercise, resulting in cramping, pain, fatigue, and discomfort.  Upon 
cessation of exercise and returning to a resting muscle state, the aching, fatigue, and 
cramping disappears.  Hence the term intermittent claudication is often used to describe 
this condition.  Claudication is one of the first manifestations of PAD and is an early 
indicator of the onset of muscle disease.  In Latin the term claudication literally means 
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‘limping’.  These symptoms are most commonly experienced in the lower limb 
musculature such as the calf muscle, but also occur in the thigh or buttocks.  
The pathophysiology of claudication is more complex than what can be explained 
by the mismatch of blood flow and oxygen demand (Hirsch et al., 2006).  The 
pathophysiology of claudication involves more complex events such as metabolic, 
neurological, and inflammatory responses (Hirsch et al., 2006).  In fact, all of the 
physiological changes that occur during claudication are not fully understood.   
Critical limb ischemia (CLI) is an advanced stage of PAD in which, patients 
experience pain due to inadequate blood perfusion while at rest (Hirsch et al., 2006).  
Unlike claudicating patients, CLI patients experience rest pain because they have muscle 
damage, neurological damage, and have increased blockages that produce a mismatch in 
oxygen supply and demand even while at rest.  This condition often produces non-healing 
foot ulcers, gangrene, and often leads to amputation.  The pain associated with CLI can 
be intense and often disturbs sleep.  Some investigators have even reported that the 
quality of life, for a CLI patient, can be worse than patients with terminal cancer (Vale et 
al., 2001; Dormandy and Rutherford, 2000).  
2.1.8 Fontaine stages & Rutherford’s categories 
The Fontaine and Rutherford classification schemas provide further methods of 
stratification for the diagnosis of PAD, beyond the use of ABIs.  These methods are not 
typically used in everyday clinical practice and are more widely used in research studies.  
The Fontaine stages of PAD were among the first clinical classifications of PAD, 
developed in 1954.  Fontaine et al. identified four stages of PAD, displayed in Table 2.1 
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(Fontaine et al., 1954).   In Fontaine Stage I, patients do not present with claudication or 
critical limb ischemia and are considered asymptomatic.  Fontaine Stage II is divided into 
two subcategories, namely stage IIa and stage IIb.  In stage IIa patients begin to 
experience intermittent claudication after walking distances greater than 200 m. In stage 
IIb patients begin to experience intermittent claudication before reaching a walking 
distance of 200 m. Stage III characterizes patients who begin to have rest pain, while 
stage IV patients present with ischemic ulcers or gangrene.  The Rutherford classification 
is a slightly more recent modification of the Fontaine stages, with a higher level of detail 
for the variation observed in the progression of PAD.  The Rutherford classification 
schema includes six clinical categories to classify PAD patients (Rutherford et al., 1997).    
Table 2.1.  Fontaine stages and Rutherford categories are often used in research studies to 
quantify stages and progression of PAD. Source: (Fontaine et al., 1954; Rutherford et al., 
1997) 
FONTAINE RUTHERFORD 
Stage Clinical Category Clinical 
I Asymptomatic 0 Asymptomatic 
IIa 
Mild 
claudication 
1 
Mild 
claudication 
IIb 
Moderate-
severe 
claudication 
2 
Moderate 
claudication 
 
 
3 
Severe 
claudication 
III 
Ischemic rest 
pain 
4 
Ischemic rest 
pain 
IV 
Ulceration or 
gangrene 
5 
Minor tissue 
loss 
 
 
6 
Ulceration or 
gangrene 
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2.2 MUSCLE MORPHOLOGY 
2.2.1 Muscle Ultrastructure 
Human skeletal muscle is made up of a complex three dimensional arrangement 
of numerous myofibers, myofibrils, and myofilaments.  Individual myofibers are bundled 
together to form fascicles, as shown in Figure 2.6.  Encircling each fascicle is a very thin 
connective tissue known as the perimysium.  Within the fascicle, each myofiber is 
encapsulated by another connective tissue known as the endomysium, which is situated 
above the sarcolemma (muscle cell membrane) that surrounds the individual myofibers.  
 
Figure 2.6. Organization of mammalian skeletal muscle structure.  Image courtesy of 
(Silverthorn, 2004) 
 
A muscle fiber is a multinucleate cell that is further made up of many individual 
units of myofibrils Figure 2.7.  Most of the intracellular volume of the muscle fiber 
consists of myofibrils.  In fact, each muscle fiber can contain up to a thousand myofibrils 
(Silverthorn, 2004).  Within the myofiber and below the sarcolemma, each myofibril is 
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surrounded by the sarcoplasmic reticulum (SR), shown in Figure 2.7.  The sarcoplasmic 
reticulum plays an integral part in the sequestration and release of calcium during muscle 
contraction.   
 
Figure 2.7. Ultrastructure of an individual myofiber made up of many myofibrils. Image 
courtesy of (Silverthorn, 2004).  
 
Myofibrils, which make up individual myofibers, consist of yet another complex 
architecture of elements known as myofilaments, as seen on Figure 2.8.  There are two 
main contractile protein myofilaments, namely the F-actin thin filaments and the myosin 
thick filaments.  The myofibril also contains other regulatory proteins, such as 
tropomyosin and troponin.  A zigzag structure known as the Z-disk serves as an 
attachment site for the thin filaments, whereas an M-line serves as the attachment site for 
the thick filaments.  Together, the Z-disk, M-line, and thick and thin filaments form a 
lattice structure within which the thick and thin filaments overlap each other at their ends 
and lay parallel to one another (Bloom and Fawcett, 1986).  A muscle myofibril consists 
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of a repeating pattern of Z-disks, and thick and thin filaments.  One section of the 
myofibril pattern, from Z-disk to Z-disk, consists of a sarcomere.  
 
Figure 2.8. Micro-architecture of myofibrils and myofilaments.  Image courtesy of 
(Silverthorn, 2004) 
  
A sarcomere is the smallest contractile unit of the muscle.  The overlapping 
portions of the thick and thin filaments within the sarcomere are connected via myosin 
heads known as cross-bridges.  The myosin heads are clustered on the ends of the myosin 
thick filaments.  The repeating sections of overlapping thick and thin filaments create 
striated band patterns that can be seen in muscle tissue.  The M-line and thick filaments 
make up the A-band, whereas the Z-disk and thin filaments make up the I-band.  The H-
zone is the portion in the middle of the thick filaments where there is no overlap with thin 
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filaments (Guyton and Hall, 2006).  When viewed on end, each thick filament is 
encircled about by six thin filaments.  The myosin heads of the thick filament have a 
natural affinity to the F-actin thin filament binding sites.  Hence the natural state of the 
muscle is rigor; however, in living muscle, relaxation is allowed to occur due to the 
presence of adenosine triphosphate (ATP) and regulatory proteins such as troponin and 
tropomyosin (Rayment et al., 1993). 
2.2.2 Contraction-Relaxation cycle of muscle 
The sliding filament theory explains that as a muscle contracts the Z-disks of the 
sarcomere move closer together, but the A-band stays the same length.  Additionally, as 
the muscle contracts the I-band and H-zone almost completely disappear.  These 
observations suggest that the thick and thin filaments slide past each other, pulling the Z-
disks closer together and causing contraction.  The force that slides the thin filament 
along the thick filament comes from the myosin heads of the thick filament.   
Myosin heads play a key role in muscle contraction because they are able to bind 
and hydrolyze adenosine triphosphate (ATP).  Each myosin head is a motor protein that 
is able to convert chemical bond energy into mechanical energy.  The myosin heads are 
essentially enzymes (ATPase) that can convert ATP into adenosine diphospate (ADP).  
The thick filaments have many myosin heads that can swivel and bind to the thin 
filaments.       
The muscle contraction-relaxation cycle begins with the muscle in the rigor state.  
In living muscle, the rigor state occurs for only a short moment until ATP binds to the 
myosin heads resulting in conformational changes that alter the actin binding affinity of 
the myosin head.  The binding site of the myosin heads then close in around the ATP 
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molecule hydrolyzing it to ADP and inorganic phosphate.  The energy released causes the 
myosin head to rotate into a 90
o
 position and connect to the next thin filament binding 
site (Silverthorn, 2004).  The rotation to the 90
o
 position cocks the myosin head back, 
giving it stored potential energy to execute the power stroke.  The power stroke begins by 
releasing the high energy inorganic phosphate molecule causing the myosin head to 
spring back to a 45
o
 position.  As the myosin head rotates back to the 45
o
 position, it 
pushes the thin filament toward the center of the sarcomere.  At the end of the power 
stroke, ADP is fully released, leaving the myosin head attached to the actin binding site 
of the thin filament resuming the rigor state (Guyton and Hall, 2006). 
 Muscle contraction is regulated by two regulatory proteins, troponin and 
tropomyosin.  Tropomyosin is an elongated protein that wraps around the thin filament.  
Tropomyosin regulates the contraction-relaxation cycle by covering the myosin binding 
site of the thin filament.  The position of tropomyosin is controlled by a calcium binding 
protein, troponin.  In the presence of high calcium concentrations, troponin causes a shift 
in tropymyosin exposing the myosin binding side allowing contraction to occur 
(Silverthorn, 2004).   
PAD patients often experience ambulatory pain caused by inadequate blood flow 
to the muscles in the lower extremities.  These ischemic conditions do not allow the 
contraction-relaxation cycle to operate normally.  In fact, the whole cycle slows 
significantly as the internal leg environment changes from aerobic to anaerobic 
conditions, shutting down the Krebs cycle resulting in a significant decrease in ATP 
energy production (Silverthorn, 2004).  Hence, PAD patients often experience cramping, 
fatigue, and aching in the lower limb musculature (Hirsch et al., 2006; Norgren et al., 
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2007).  Ambulatory pain due to the mismatch in oxygen supply and demand is known as 
claudication.  Claudication is one of the first and most common manifestations of PAD 
and is an early indicator of the onset of muscle disease.   
2.2.3 Morphology 
PAD produces a progressive accumulation of ischemic injury to the limbs. This 
ischemic injury is reflected in a gradual worsening in the microscopic morphology of the 
gastrocnemius (calf muscle).  Morphological analyses of PAD muscle degeneration have 
been thus far largely qualitative by pathologists’ subjective visual inspection of muscle 
tissue with a microscope.  Qualitative histological descriptions are useful, however, 
objective, quantitative determinations offer greater precision and reproducibility for 
scientific study as well as diagnosis and prognosis.  
Figure 2.9 displays the morphology of normal muscle which has polygonal  
myofibers of uniform size and shape, fascicles with thin perimysium, and peripherally 
located nuclei.  Moderately myopathic muscle cells, from a patient with claudication, 
have an increased variation in shape and size and begin to develop fiber vacuolization 
and target lesion with centrally located nuclei, as shown in Figure 2.10.   
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Figure 2.9. Healthy, normal muscle morphology.  
 
Figure 2.10.  Moderate myopathic myofibers from a PAD patient.  
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In severely myopathic myofibers (Figure 2.11), from a patient with critical limb 
ischemia, group atrophy begins to appear with myofiber vacuolization, target lesions, 
centrally located nuclei, and thicker interstitial tissue that is more fibrotic.  At this stage, 
some myofibers will have lost 90% of their contractile element.  As injury advances, the 
patients’ clinical condition deteriorates from being asymptomatic to having claudication 
and then developing critical limb ischemia.  Thus, morphology of myofibers changes 
during the progression of PAD.   
  
 
 
Figure 2.11.  Severely myopathic myofibers from a PAD patient. 
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2.3 OXIDATIVE DAMAGE 
The pathophysiology of PAD and its end-organ effects are more complex than 
what can be explained by the mismatch of blood flow and oxygen demand (Hirsch et al., 
2006).  In the past, it was presumed that the manifestations of PAD were solely due to the 
atherosclerotic blockages and reduced blood flow to the limbs.  However, literature 
reports indicate that there is a myopathy secondary to the vascular disease (Pipinos et al., 
2008b; Pipinos et al., 2008a).  During walking, patients presenting with atherosclerotic 
blockages in the arteries supplying their legs, experience aching, fatigue, and or cramping 
as the increased metabolic needs of the limb are not being met.  During rest, the 
metabolic demands of the limb return to baseline and the leg is re-perfused.  An 
increasing number of studies suggest that these repeated cycles of ischemia followed by 
reperfusion trigger inflammatory responses, compromise cellular bioenergetics, and 
generate reactive oxygen species (Pipinos et al., 2008a).  Additional pathophysiological 
events occur at the neurological level as well (Hirsch et al., 2006).   
2.3.1 Mitochondria and the Electron Transport Chain (ETC) 
Mitochondria are tubular organelles, found in the cytoplasm, that play a primary 
role in energy production, formation and disposal of reactive oxygen species, and as 
apoptosis regulators.  Mitochondria are commonly referred to as the power house of the 
cell.  The mitochondrial matrix, within the mitochondria, is composed of several 
compartments that carry out specific energy production operations within the oxidative 
phosphorylation process.  Oxidative phosphorylation is a metabolic pathway that 
converts adenosine diphosphate (ADP) into adenosine triphosphate (ATP) via the energy 
released by the degradation of carbohydrates, pyruvate, fatty acids, and amino acids 
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(Nelson and Cox, 2004).  ATP is one of the primary sources of energy that directly 
influences muscle performance in the human body and is often referred to as the currency 
of intracellular energy transfer (Knowles, 1980).   
During the oxidative phosphorylation, electrons are transferred along a series of 
protein complexes known as the electron transport chain (ETC), displayed in Figure 
2.12.  Energy is generated through a series of reduction and oxidation reactions.  Energy 
generated due to electrons flowing through the electron transport chain is used to 
transport protons across the mitochondrial membrane creating a proton gradient.  The 
electron transfer releases and the proton motive force generate approximately 200 kJ per 
mole that can be used in the formation of ATP (Nelson and Cox, 2004).  In the final 
stage, protons are allowed to flow back across the mitochondrial membrane and a 
rotational catalysis enzyme complex captures the energy produced by the proton flow, 
which allows the synthesis of ATP, shown in Figure 2.12.  
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Figure 2.12.   Within the mitochondria ATP synthesis is driven by the energy produced 
via the electron flow along the electron transport chain and the generated proton gradient. 
Image courtesy of (Nelson and Cox, 2004). 
 
During cellular respiration, in which energy production is driven by oxidation, 
harmful intermediates are often produced.  For instance, reactive oxygen species can be 
created at complex I and complex III, during the oxidative phosphorylation process 
(Nelson and Cox, 2004).  One of these reactive oxygen species is a superoxide free 
radical, which when converted to a hydroxyl radical it can damage other proteins, 
enzymes, membrane lipids, and nucleic acids.  To dispose of these harmful free radicals, 
cells contain numerous antioxidant systems to counteract, detoxify, and limit damage to 
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the cell. Superoxide free radicals are inactivated by a set of protective enzymes including 
superoxide dismutase and glutathione peroxidase.   Superoxide dismutase converts 
superoxide free radicals to hydrogen peroxide and glutathione peroxidase renders the 
hydrogen peroxide harmless, as shown in Figure 2.13.   
 
Figure 2.13.  Reactive oxygen species can be produced at complexes I and III in the 
electron transfer chain.  Superoxide dismutase is an antioxidant enzyme that helps render 
free radicals harmless. Image courtesy of (Nelson and Cox, 2004) 
  
Besides their primary role in energy production, mitochondria also participate in 
regulating apoptosis.  Apoptosis is a process of controlled cellular damage and death, 
which takes place for the good of the organism to renew its cells.  When cells receive an 
external signal that triggers apoptosis, one consequence is an increase in the permeability 
of the mitochondrial membrane, causing the release of cytochrome c (Nelson and Cox, 
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2004).  Note that cytochrome c has a dual functionality.  Before the cell receives 
signaling to begin apoptosis, cytochrome c is normally used in the transfer of electrons 
between complexes III and IV within the electron transport chain.  After receiving the 
apoptotic signal cytochrome c is released to the cytoplasm where it binds to apoptotic 
protease activating factors and activates proteolytic enzymes that degrade proteins.   
In summary, mitochondria play a multilevel role that consists of energy 
production, disposal of oxygen radical species, and regulation of apoptosis.  Therefore, 
dysfunction of the mitochondria would launch a cascade of problems that include a 
decrease in energy production, increase in reactive oxygen species, defects in the 
antioxidant abilities (superoxide dismutase enzymes).  These events lead to damaged 
mitochondrial DNA, and damage to apoptotic regulators.  Mitochondrial studies in PAD 
patients have revealed that PAD patients may have damaged mitochondria in addition to 
reduced blood flow from arterial blockages (Pipinos et al., 2008; Pipinos et al., 2008b; 
Pipinos et al., 2008a).  These studies suggest that there is a mitochondriopathy that may 
be a factor in PAD pathogenesis.   
2.3.2 Mitochondriopathy 
In the past, it was presumed that the only determinant of functional impairment in 
PAD patients was solely due to atherosclerotic blockages and reduced blood flow to the 
limbs.  However, the pathophysiology of PAD and its end-organ effects is more complex 
than what can be explained by the mismatch of blood flow and oxygen demand (Hirsch et 
al., 2006).  The idea that PAD patients may have a myopathy related to impaired 
mitochondria was first introduced by Dahllof et al. in the early 1970’s.  This group 
performed an investigation in which they demonstrated that carbohydrate 
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supplementation significantly increased muscle glycogen content and improved walking 
performance (Dahllof et al., 1975).  The investigation was further carried out by Hou et 
al. who observed, by isolating mitochondria from PAD patients’ calf muscle, that the rate 
of carbohydrate oxidation in the mitochondria were positively correlated with walking 
performance and that carbohydrate metabolism was linked to impaired oxygen kinetics at 
the onset of exercise (Hou et al., 2002).  These data suggest that mitochondria in PAD 
patients may be defective in carbohydrate oxidation and that carbohydrate 
supplementation may be beneficial to improve walking parameters.   
2.3.3 In vivo & In vitro evaluation of PAD mitochondria dysfunction 
Additional evidence of mitochondrial dysfunction was demonstrated by Pipinos et 
al. as they evaluated mitochondrial bioenergetics in vivo using phosphorus-31 nuclear 
magnetic resonance spectroscopy (MRS).  The MRS technology allowed them to 
evaluate concentrations of ATP, phosphocreatine, and intracellular pH in real time.  They 
concluded, based on the MRS data, that indeed PAD mitochondria do not function 
normally, and reflected an impairment of skeletal muscle bioenergetics metabolism. 
(Pipinos et al., 2000)  However, they also concluded that a major limitation in this 
method was the inability to control or measure the external mitochondrial environment as 
well as the differences in bioenergetics due to blood flow.   
An investigation by Pipinos et al. (2006) further defined what components within 
PAD mitochondria were failing and causing decreased bioenergetics (Pipinos et al., 
2006).  In this study, they examined PAD mitochondrial oxidative phosphorylation in 
vitro in a controlled environment with ample oxygen availability.  The results of this 
study confirmed that PAD skeletal myofibers had significantly decreased oxygen 
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consumption and pointed out that the defect was coming from the electron transport 
chain.  They evaluated the individual complexes I through IV using in vitro respirometry 
and spectrophotometric techniques to evaluate the complexes enzymatic activity in order 
to isolate the defects.  They found that complexes I, III, and IV, of the electron transport 
chain had significantly lower mitochondrial respiration with 17%, 30%, and 17% 
decreases, respectively.  Similarly they found that complexes I, III, and IV also had lower 
percentages of enzymatic activities at 22%, 15%, and 32% decreases, respectively 
(Pipinos et al., 2006).  These finding confirmed the presence of dysfunctional 
mitochondria that have defects within the electron transport chain. The 
mitochondriopathy is manifested by the decreased bioenergetics. 
2.3.4 Oxidatively altered proteins 
Dysfunctional mitochondria, especially with defects in complexes I and III, are 
likely to generate enhanced amounts of free radicals.  Small amounts of superoxide free 
radicals occur naturally during the oxidative phosphorylation process, but when there are 
defects in the complexes of the ETC, an increased amount of free radicals can be 
expected.  In this light and based on the results demonstrated by Pipinos et al., that show 
defects in complexes I and III from PAD patients, it can be expected that PAD muscle 
may generate significant amounts of reactive oxygen species (Pipinos et al., 2006).  If 
there are in fact elevated levels of reactive oxygen species, it would be reflected in an 
increased protein carbonylation and lipid peroxidation products.  As such, Pipinos et al. 
also evaluated PAD muscle for protein and lipid oxidative damage.  They demonstrated 
that PAD skeletal muscle had significantly elevated levels of both protein carbonyls and 
lipid hydroperoxide (Pipinos et al., 2006).    
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Physiological studies of patients with PAD can contain a lot of variation, due to 
the presence of comorbidities, level of severity, and mode of presentation.  Therefore, 
Pipinos et al. confirmed their previous findings in a controlled study with rodents 
subjected to inflow arterial ligation to resemble moderate to severe PAD (Pipinos et al., 
2008).  They hypothesized that in the absence of comorbidities (i.e. diabetes, smoking, 
etc. found in human studies) they would still see myopathy with mitochondrial 
dysfunction and oxidative damage.  The results obtained with the chronically ischemic 
mouse model were consistent with the results found in the human PAD muscle studies.  
Again they found that the skeletal muscle from the ischemic mouse sustained substantial 
oxidative injuries with increased protein carbonylation and lipid peroxidation (Pipinos et 
al., 2008).  Increased 4-hydroxy-2-nonenal (HNE), which is produced during lipid 
peroxidation, appears in higher quantities during oxidative stress.  To test for elevated 
levels of lipid peroxidation, they labeled mouse muscle cross-sections mounted on slides 
with fluorescent biomarkers specific for HNE-protein adducts.  Figure 2.14 illustrates 
that ischemic mouse muscle had higher levels of HNE adducts, indicated by increased 
labeling of the HNE fluorescent biomarker, yielding a brighter image compared to the 
control mouse muscle. 
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Figure 2.14.  A) Control and B) ischemic mouse muscle were labeled with fluorescent 
biomarkers specific for HNE-protein adducts.  Evidence of lipid peroxidation is 
manifested by increased levels of 4-hydroxy-2-nonenal (HNE) labeling, yielding a 
brighter image in the ischemic mouse muscle. Image source: (Pipinos et al., 2008) 
 
Additionally, the authors evaluated the abundance of mitochondria within the 
mouse muscle and also labeled for expressions of ATP synthase and manganese 
superoxide dismutase (Pipinos et al., 2008).  They found that the ischemic muscle 
exhibited increased ATP synthase, and had higher expressions of manganese superoxide 
dismutase when compared to control mouse muscle.  Figure 2.15 B & D illustrates 
higher labeling intensity for ATP synthase indicating higher mitochondrial content in the 
ischemic mouse muscle.  Pipinos et al. (2008) reported that although there was an 
increase in mitochondrial content in the ischemic mouse muscle, the respiration or 
oxidative phosphorylation was still lower compared to the controls.  These results were 
consistent with other work indicating that PAD is associated with a significant increase in 
mitochondrial content in skeletal muscle (Brass and Hiatt, 2000). Figure 2.15 F presents 
higher labeling intensity for manganese superoxide dismutase, which is part of the 
antioxidant defense for cells and is an enzyme that renders superoxide free radicals 
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harmless.  The higher intensity labeling of this enzyme indicates that there are higher 
levels of oxidative stress in the ischemic mouse muscle compared to the controls.   
 
Figure 2.15.  A & C present control and B & D present ischemic mouse muscle labeled 
with antibodies against ATP synthase, where A & B are at a higher magnification. The 
higher intensity labeling in B & D indicate higher mitochondrial content in ischemic 
mouse muscle.  E presents control and F presents ischemic mouse muscle labeled with 
monoclonal antibodies specific for manganese superoxide dismutase.  The higher 
intensity in E indicates higher levels of the dismutase in ischemic mouse muscle. Source: 
(Pipinos et al., 2008) 
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All of these findings support the idea that PAD is not exclusively a consequence 
of compromised blood flow, but also includes a myopathy with mitochondrial 
dysfunction that yields decreased bioenergetics and produces oxidative damage to the 
muscle cells.  
2.4 VIBRATIONAL SPECTROSCOPY 
2.4.1 Electromagnetic radiation 
Electromagnetic radiation (light) is a complex form of energy that has both 
electric and magnetic field components and exhibits wave like behavior as it travels 
through space (Pedrotti et al., 2007).  Propagation of electromagnetic radiation is 
mathematically quantified by its frequency (ν), wavelength (λ), and characteristic speed 
(c= 3 x 10
8
 m/s).  The relationship between wavelength (m), frequency (Hz or s
-1
), and 
velocity (m/s) of light is given in Equation (2.1. 
   
 
 
 (2.1) 
Electromagnetic radiation carries energy away from its source as it propagates 
through space.  The amount of energy is directly proportional to the frequency of the 
electromagnetic radiation and inversely proportional to wavelength. The relationship 
between energy (J) and frequency is given in Equation (2.2.  
 
       
 
 
 (2.2) 
Where E is energy (J) and h is Planck’s proportionality constant 6.626 x 10-34 (J∙s).  The 
distribution of energy levels, from the range of various frequencies, makes up the 
electromagnetic spectrum, shown in Figure 2.16.  High energy electromagnetic 
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radiations, such as gamma rays and x-rays, have short wavelengths and high frequencies, 
whereas, low energy electromagnetic radiation, such as infrared and radio, have long 
wavelengths and low frequencies.  
 
Figure 2.16. Electromagnetic spectrum.  Image courtesy of (Pedrotti et al., 2007) 
2.4.2 Spectroscopy 
Spectroscopy is a science that quantifies interactions between electromagnetic 
radiation and matter in terms of absorption, transmission, or scattering radiation 
signatures.  Electromagnetic interactions with molecules can often provide insight into 
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the molecular structure, vibrations, and rotations of complex molecules. These 
interactions can be used to identify properties of biochemical compounds (Burns and 
Ciurczak, 2001).  Specifically, light in the ultraviolet and near-infrared regions are 
especially useful in identifying organic compounds.  Spectroscopic data is often 
presented in the form of a spectral plot with radiation intensity recorded as a function of 
wavelength or frequency.   
The theory behind spectroscopy involves central concepts such as resonance 
frequencies, quantum mechanics, and the different virtual energy states that molecules 
can possess.  In quantum mechanics, all molecules have unique energy differences 
between their ground state (stable state) and their excited virtual state (unstable state).  
All molecules vibrate at specific frequencies. When the frequency of the electromagnetic 
radiation matches the frequency of the molecule, resonance takes place and an absorption 
signature can be detected.  Light interaction with biochemicals at the molecular level 
result in changes of the energy state due to light energy being absorbed.  The absorbed 
energy causes electrons to transition from one orbital to another.  Within the infrared 
region of the electromagnetic spectrum, most organic compounds will have prominent 
absorption bands that correspond to vibrational energies of the compound.  The region in 
which these prominent bands occur is known as the fingerprint region, which is 
especially useful in identifying molecules and functional groups.  
2.4.3 Light Scattering 
Light scattering occurs when an incident beam of light encounters a scattering 
center which results in a deflection or changing of direction of the incident photons.  
There are three common forms of light scattering namely, Rayleigh, Mie, and Raman 
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scattering.  Rayleigh and Mie scattering are elastic forms of light scattering, meaning that 
the scattered light is deflected at the same frequency as the incident beam of light.  
Whereas, Raman scattering is an inelastic form of light scattering, in which the scattered 
light is re-emitted at a different frequency than the incident beam of light.  The majority 
of light scattering is due to Rayleigh and Mie scattering. 
Scattering is more effective when scattering centers are small particles in 
comparison to the wavelength of the electromagnetic radiation.  Rayleigh scattering is 
predominantly due to particles whose dimensions are smaller than the radiation 
wavelength (Wolfson, 1999).  An example of Rayleigh scattering is the scattering that 
occurs when sunlight interacts with oxygen and nitrogen molecules in the atmosphere 
(Wolfson, 1999).  It has been found that scattering is more effective at shorter 
wavelengths and higher frequencies (Pedrotti, 2007).  This is apparent in the sky 
appearing as blue; higher frequency blue light is scattered more so than lower frequency 
red light.  In fact, the scattering power of violet light (λ = 400 nm) is approximately 10 
times as great as that of red light (λ = 700 nm) (Pedrotti, 2007).  
 Light scattering that occurs due to larger particles, whose size is larger relative to 
the wavelength of light, is known as Mie scattering.  Mie scattering occurs in mediums 
such as powdered materials like sugar where light scattering is due to the surface with 
larger particles.  In a medium in which many oscillators are closer together, a cooperative 
effect tends to cancel the scattering in all directions except along the reflection and 
refraction directions (Pedrotti, 2007).  However, in material that has particles that are not 
perfectly ordered in a constant atomic arrangement light is scattered in other directions as 
well.  Although materials that have predominately Mie scattering centers have less 
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scattering power, the density of oscillators leads to a considerable scattering signal 
(Pedrotti, 2007).   
2.4.4 Raman Spectroscopy 
Most photons are elastically scattered through Rayleigh and Mie scattering.  
However, a small fraction of photons, approximately 1 in 10
7
 photons will scatter in an 
inelastic manner, meaning they will undergo a change in energy compared to the incident 
photons. The inelastic scattering of photons is known as the Raman Effect.  Prior to the 
early 1900’s inelastic scattered photons were thought to be just noise because they 
produced a very weak signal.  However, in 1928 C.V. Raman found that despite the weak 
signal of these photons, they were molecule specific and could be used to identify 
unknown compounds.   
Raman scattering occurs when energy from an incident wave of light is removed 
by a scattering medium via an inelastic collision (Pedrotti, 2007).  As light interacts with 
elemental oscillators or scattering units, the vibrations of the scattering unit are forced 
into higher oscillations due to the alternating electric field of the incident wave of light.  
The excited molecules reradiate or scatter the energy with frequencies higher or less than 
the incident photons (Pedrotti, 2007).  The change in energy level due to the Raman 
Effect is called a Raman shift.  If the Raman shift results in a decrease in energy it is 
called Stokes Raman scattering.  In other words, in Stokes Raman scattering the scattered 
photon will have less energy or a longer wavelength of light compared to the excitation 
incident photon.  The loss of energy comes from the inelastic collision between the 
photon and the molecule.  Whereas, if the Raman shift yields a net increase in energy it is 
called anti-Stokes Raman scattering.  In anti-Stokes Raman scattering the scattered 
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photon will have a shorter wavelength or higher energy level than the incident photon. 
Figure 2.17 displays an energy diagram that illustrates the changes in energy levels in IR, 
Rayleigh (elastic scattering), and Stokes and Anti-Stokes Raman scattering.  In Raman 
scattering the energy gained or lost corresponds to the vibrational energy spacing in the 
molecules.   
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Figure 2.17.  Energy diagram depicting elastic Rayleigh scattering and Stokes and Anti-
Stokes Raman scattering. (Sasic and Ozaki, 2010) 
 
Fluorescence is also a process that involves molecular excitation followed by 
emission of a photon (Sasic and Ozaki, 2010).  Although, fluorescence operates under 
similar principles as Raman it is fundamentally different.  In fluorescence, molecules are 
excited to a discrete energy level, whereas, in Raman molecules can become excited to 
much higher virtual energy states that are explained by involving quantum physics (Sasic 
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and Ozaki, 2010).  In fluorescence, molecular excitation occurs via absorption, whereas, 
in the Raman Effect an inelastic collision causes the photon to gain or lose a vibrational 
quantum of energy (Sasic and Ozaki, 2010).  Moreover, Raman spectra produce sharp 
spectral peaks that are molecule specific, whereas, fluorescence emissions are usually 
broad with few spectral features.  Despite their differences, both fluorescence signals and 
Raman signals are present in Raman spectra.  The Raman peaks usually ride on top of the 
background autofluorescence signal.  In Raman spectra the fluorescence signal is 
generally not useful and is subtracted out via baseline correction procedures.    
2.4.5 Raman active molecules vs. IR active molecules 
Raman and Infrared spectroscopy both rely on vibrational energies of molecules 
for detection, but each method has different selection rules (Sasic and Ozaki, 2010).  In 
other words, molecules that produce Raman spectral peaks generally will not appear in IR 
spectra and vice versa molecules that generate IR spectral peaks will not appear in Raman 
spectra.  These selection rules are useful because they make the two spectroscopic 
methods complementary to each other.  The selection rules are related to the symmetry of 
the molecule.  Molecules with a symmetric configuration are said to be Raman active 
because they will produce a peak in the Raman spectra (Sasic and Ozaki, 2010).  For 
instance, ethylene’s carbon-double-carbon (C=C), which has symmetry, will produce a 
peak in Raman spectra around 1657 cm
-1
 (Movasaghi et al., 2007).  Conversely, IR 
selection rules favor asymmetric molecules.  Molecules that have an asymmetrical 
configuration are said to be IR active, because they will produce peaks in IR spectra 
(Sasic and Ozaki, 2010).  For example, a carbonyl (C=O), which has an asymmetrical 
configuration, will produce an IR spectral peak at around 1700 cm
-1
 (Sasic and Ozaki, 
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2010).  Figure 2.18 presents both Raman scattering and Fourier transform infrared 
(FTIR) spectra of oleic acid methyl ester.  The selection rules are evident in Figure 2.18, 
in which the C=C bond produces a peak in the Raman spectra and does not in the FTIR 
spectra.  The opposite is true for the carbonyl (C=O), producing a peak in FTIR and not 
in Raman.  The nature of these selection rules can become very useful, to identify 
unknown compounds, using the two methods in a complementary fashion (McCreery, 
2000).   
 
Figure 2.18. Raman scattering (lower) and FTIR (upper) spectra of oleic acid methyl 
ester, depict the selection rules of each spectroscopic method and their complementary 
nature. Source: (McCreery, 2000) 
 
2.4.6 Biomedical applications of spectroscopy 
Raman spectroscopy has been a well-accepted analytic method in detecting 
biological and chemical materials.  Studies have demonstrated that Raman spectroscopy 
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is capable of identifying and constructing chemical maps of subcellular structures such 
as, the nucleus, cytoplasm, and mitochondria (Miljković et al., 2010; Bonnier et al., 
2010).  In fact, the whole process of eukaryotic cell mitosis has been traced using time 
and space resolved Raman spectra of organelles from dividing yeast cells (Huang et al., 
2003).  Raman spectroscopy of biological tissues can provide information-rich, 
biochemical profiles (Diem et al., 1999).  
Raman spectroscopy has been used as a method for the detection of high-risk 
plaques in patients with cardiovascular disease.  The term, high-risk plaque, also referred 
to as vulnerable plaque, describes plaque that is lipid-rich with a thin fibrous cap 
(MacNeill et al., 2003).  This type of plaque buildup generally has modest stenosis and 
therefore is not easily identified as threatening, but often results in acute coronary 
syndromes and sudden cardiac death (Muller et al., 1989).  Baraga et al. developed a 
Raman probe that could be used in situ to collect optical histochemistry of the arteries 
(Baraga et al., 1992).  The standard for characterizing atherosclerotic plaque buildup 
relies primarily on morphology and extent of stenosis from the plaque.  This study 
provided unprecedented in vivo and in situ biochemical information of the plaque within 
the arteries.  The Raman probe was able to provide real time in vivo and in situ 
information about the plaque composition, including cholesterol, elastin, collagen, lipids, 
carotenoids, and calcium apatite deposits (Baraga et al., 1992).  The authors also 
remarked that this technique could collect spectral information up to 1.5 mm below the 
surface allowing further histological information about the plaque.   
In another study, Buschman et al. also demonstrated that Raman spectroscopy 
could be used to aid in the diagnosis of coronary atherosclerosis.  Raman spectra were 
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collected from coronary arteries (n=200) using a Raman microscope (Buschman et al., 
2001).  They developed a logistic regression model to classify coronary artery samples as 
nonatherosclerotic, calcified plaque, or noncalcified atheromatous plaque.  They reported 
that their model was able to correctly classify, in a validation data set (n=87), the status of 
the artery plaque with 94% accuracy (Buschman et al., 2001).   Figure 2.19 displays 
Raman spectra from their study of a normal artery, artery with lipid rich plaque, and an 
artery with calcified plaque.     
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Figure 2.19.  Raman spectra of A) normal artery, B) artery with lipid rich plaque, and C) 
artery with calcified plaque.  The bottom line in each spectra is the residual between the 
Raman spectra and a fitted model.  Source: (Buschman et al., 2001)   
  
In an investigation of Raman spectroscopy using live yeast cell mitochondrion, an 
important discovery was made that associated a Raman spectral peak (1602 cm
-1
) with 
mitochondrial activity.  The authors named this peak the Raman spectral signature of life 
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because it reflected the metabolic activity of the mitochondria (Huang, 2004).  They 
originally noticed this peak in the cytoplasm of a living Schizosaccharomyces pombe cell 
and noticed that it appeared concomitant with the bands of phospholipids.  To investigate 
the origin of the 1602 cm
-1
 peak and to confirm that this peak was related to 
mitochondrial activity, the authors added aqueous potassium cyanide (KCN) to yeast 
cells and recorded Raman spectra at given time intervals.  KCN is an inorganic 
compound that inhibits cellular respiration.  Figure 2.20 displays the effects that KCN 
(respiration inhibition) had on the cell’s Raman spectra.  Prior to the addition of KCN, 
the Raman spectra displayed a 1602 cm
-1
 peak.  As time passed the 1602 cm
-1
 peak 
decreased considerably while the protein band at 1003 cm
-1
 did not change.  Additionally, 
other phospholipid bands 1446 and 1300 cm
-1
 began to decrease as well as time passed.  
They concluded that the CN
-
 inhibited cellular respiration and caused the 1602 cm
-1
 peak 
to decrease. The decreased metabolic activities subsequently caused the double 
membrane structure of the mitochondria to degrade which was reflected as a decrease in 
the other phospholipid bands over time as well.  Therefore they concluded that these 
Raman spectral changes correspond to the dying process of living yeast cells.  However, 
the authors concluded that the exact molecular species responsible for the 1602 cm
-1
 peak 
are unknown.  Using green fluorescent proteins targeted specifically to mitochondria they 
confirmed that the Raman spectra were taken from mitochondrion inside the cell.    
56 
 
 
Figure 2.20.  Raman spectral signature associated with mitochondrial activity.  Source: 
(Huang, 2004) 
 
Other investigative studies have demonstrated the use of Raman spectroscopy for 
characterization of other diseases and have demonstrated the scientific merit of this 
technique.  These other applications include characterization of biochemical changes in 
disease progression for bronchial tissue (Koljenovic et al., 2004), brain tissue (Kirsch et 
al., 2010), stomach ulcers (Bergholt et al., 2010), articular cartilage degeneration 
(Bonifacia et al., 2010), and breast tissue (Nijssen et al., 2002).  
2.5 SUMMARY 
The fundamental problem in PAD patients is the presence of atherosclerotic 
blockages in the arteries supplying blood to their legs.  PAD affects a large range of 
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arterial beds and is often concomitant with other polyvascular diseases (Hirsch et al., 
2006; Bhatt et al., 2006).  PAD becomes more likely as one gets older and generally 
expresses symptoms such as, cramping, pain, or tiredness in the lower extremities 
(Norgren et al., 2007).   
The pathophysiology of PAD is complex and involves changes occurring on 
multiple levels including, reduced blood flow, altered metabolic processes, and muscle 
degeneration (Stewart et al., 2002).  At the level of the skeletal muscle, ischemic injury is 
manifested as a gradual and characteristic degradation of muscle histology (Pipinos et al., 
2008b; Hedberg et al., 1988b; Makitie and Teravainen, 1977; Marbini et al., 1986).  Thus 
far, attempts to characterize PAD muscle degradation have been limited to qualitative 
histopahtological assessments and limited measures of myofiber cross-sectional area 
(Hedberg et al., 1988b; Makitie and Teravainen, 1977; Farinon et al., 1984).  Further, 
repeated cycles of ischemia followed by reperfusion, trigger inflammatory pathways and 
induce the generation of reactive oxygen species (ROS) in the PAD muscle, damaging 
primary organelles such as mitochondria (Pipinos et al., 2008; McDermott et al., 2004; 
Pipinos et al., 2008b).  Dysfunctional mitochondria then further lower the already 
decreased energy levels (associated with compromised blood supply) and become sources 
of increasing levels of ROS and possibly inducers of apoptosis (McDermott et al., 2004).  
In this dissertation PAD muscle degeneration is characterized precisely with 
mathematical equations that incorporate multiple, objectively defined parameters 
including myofiber density, roundness, minor and major axes, and solidity.  Based on 
these myofiber morphometrics a discriminant model is presented, which can be used to 
objectively grade muscle damage within clinical classifications.  In addition to the 
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morphometric grading scale, this dissertation combines morphometric parameters with 
oxidative damage parameters to further enhance PAD muscle characterization.  Finally, 
this dissertation evaluates the use of Raman spectroscopy, as a label-free optical tool, to 
characterize altered muscle biochemistry in patients with PAD. 
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3.1 ABSTRACT 
Background―Peripheral arterial disease (PAD), which affects approximately 10 million 
Americans, is characterized by atherosclerosis of the non-coronary arteries.  PAD 
produces a progressive accumulation of ischemic injury to the legs, manifested as a 
gradual degradation of gastrocnemius histology.  In this study, we evaluated the 
hypothesis that quantitative morphological parameters of gastrocnemius myofibers 
change in a consistent manner during the progression of PAD, provide an objective 
grading of muscle degeneration in the ischemic limb, and correlate to clinical stage of 
PAD. 
Methods and Results―Biopsies were collected with a Bergstom needle from PAD 
patients with claudication (n=18) and critical limb ischemia (CLI; n=19) and control 
patients (n=19).  Myofiber sarcolemmas and myosin heavy chains were labeled for 
fluorescence detection and quantitative analysis of morphometric variables including 
area, roundness, perimeter, equivalent diameter, major and minor axes, solidity, and fiber 
density.  The muscle specimens were separated into training and validation data sets for 
development of a discriminant model for categorizing muscle samples on the basis of 
disease severity.  The parameters for this model included standard deviation of 
roundness, standard deviation of solidity of myofibers, and fiber density.  For the 
validation data set, the discriminant model accurately identified control (80.0% 
accuracy), claudicating (77.7% accuracy), and CLI (88.8% accuracy) patients, with an 
overall classification accuracy of 82.1%.   
Conclusions―Myofiber morphometry provided a discriminant model that establishes a 
correlation between PAD progression and advancing muscle degeneration. This model 
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effectively separated PAD and control patients and provided a grading of muscle 
degeneration within clinical stages of PAD.  
 
Keywords:  Peripheral arterial disease; Myofiber morphology; Fluorescence microscopy; 
Imaging; Linear discriminant analysis;
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3.2 INTRODUCTION 
Peripheral arterial disease (PAD) is a vascular disease characterized by stenosis of 
the non-coronary arteries caused by fatty deposits and plaque buildup (Hirsch et al., 
2006).  Although PAD affects a large range of arterial beds, most occlusions occur in the 
arteries of the legs, pelvis, and abdominal aorta causing reduced blood flow to the lower 
extremities (Hirsch et al., 2006).  PAD is a slowly progressive disease that develops over 
many years.  It is estimated that PAD affects approximately 8-10 million Americans 
(Norgren et al., 2007; Hiatt et al., 1995).  The disease becomes more common as one gets 
older and the number of affected Americans is expected to increase as the population 
ages (Feinglass et al., 1999; Allison et al., 2007). 
Intermittent claudication, walking impairment induced by simple exercise, is an 
early manifestation of PAD (Fontaine Stage 2) (Norgren et al., 2007; Fontaine et al., 
1954) and an indicator of the damage to leg muscles (Pipinos et al., 2008a; Pipinos et al., 
2008b).  More advanced disease is characterized by pain while at rest (Fontaine Stage 3) 
and non-healing foot ulcers and gangrene (Fontaine Stage 4).  The pathophysiology of 
PAD is complex and involves changes occurring on multiple levels, such as reduced 
blood flow, altered metabolic processes, oxidative damage, and degeneration of nerves 
and muscle (Stewart et al., 2002).  Currently, PAD is diagnosed primarily on the basis of 
patient complaints about pain, non-healing wounds in the legs, and reduced limb 
hemodynamics, such as the Ankle/Brachial Index (ABI; the ratio of systolic pressure in 
the ankle to that in the arm).  Stenoses and occlusions of the arteries supplying the legs 
produce low ABIs, the hemodynamic hallmark of PAD.  
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 PAD produces a progressive accumulation of ischemic injury to muscles, nerves, 
blood vessels, skin and subcutaneous tissues of the leg (Pipinos et al., 2008a; Pipinos et 
al., 2008c; Brass and Hiatt, 2000).  At the level of the skeletal muscle, this ischemic 
injury is manifested as a gradual and characteristic degradation of muscle histology 
(Pipinos et al., 2008b; Hedberg et al., 1988; Makitie and Teravainen, 1977; Marbini et al., 
1986).  We hypothesize that quantitative morphometric parameters of gastrocnemius 
myofibers change in a consistent manner during the progression of PAD, provide an 
objective grading of muscle degeneration in the ischemic limb, and correlate to clinical 
stage of PAD.  Thus, the specific objectives of this study are to 1) quantify morphological 
parameters of myofibers in gastrocnemius biopsies, 2) develop and validate a 
discriminant model using morphological parameters that classify muscles as control, 
claudicating, and CLI and 3) to grade the disease particularly in its early stage (Fontaine 
Stage 2) on the basis of morphological measurements. 
3.3 METHODS & MATERIALS 
3.3.1 Tissue Sample Collection 
 The experimental protocol was approved by the Institutional Review Board, and 
all subjects gave informed consent.  We recruited 18 patients with clinical diagnosis of 
claudication, 19 patients with clinical diagnosis of critical limb ischemia (CLI), and 19 
controls who did not have PAD (Table 3.2).  Muscle samples obtained from controls, 
claudicating, and CLI patients are designated as “control”, “claudication”, and “CLI” 
respectively throughout the manuscript. Biopsies of the gastrocnemius were acquired 
with a Bergstom needle, fixed in methacarn and embedded in paraffin.  Two 4 µm cross 
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sections, taken approximately 40 µm apart, were mounted on glass slides for fluorescence 
labeling.     
3.3.2   Fluorescence Labeling of Tissue Sections 
In preparation for labeling sarcolemma and myosin types I and II, the slide 
specimens were deparaffinized with xylene and rehydrated via a series of ethanol washes 
and distilled water.  The rehydrated slide specimens were heated at 94 
o
C in Tris buffer 
(pH 9.0) for 30 minutes and then allowed to cool for 20 minutes.  The slide specimens 
were soaked in SuperSensitive Wash buffer (SS; BioGenex Laboratories, Inc., Freemont, 
CA) for 30 minutes at room temperature, with stirring.  A pap pen was used to apply a 
lipid barrier on dried areas around the tissue specimens.  While applying the lipid barrier, 
care was taken to ensure that the tissue specimens were kept moist.   
 A programmable autostainer (BioGenex i6000; BioGenex Laboratories) was used 
to label sarcolemma and myosin heavy chains.  The slide specimens were washed ten 
times with SS buffer (4 min per wash) then blocked with 10% goat serum for 20 minutes.  
Subsequently, the slides were treated with a mixture of anti-Type I myosin (Sigma-
Aldrich, St. Louis, MO; M8421, clone NOQ7.5.4D) and anti-Type II Myosin (Sigma-
Aldrich; M4276, clone MY-32) antibodies, for 1 hour. The slide specimens were washed 
two times with SS buffer (4 min per wash) and then treated for 1 hour with a mixture of 
wheat germ agglutinin-Alexa Fluor 350 to label the sarcolemma (Life Technologies-
Molecular Probes, Grand Island, NY; W11263) and goat anti-mouse IgG-Alexa Fluor 
488 (Life Technologies-Molecular Probes; A11004).  Treated slides were washed three 
times with SS buffer.  Finally, ProLong Gold antifade medium (Life Technologies-
Molecular Probes; P36930) was applied to the labeled specimens and covered with a 
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coverslip.  The slides were stored at room temperature for 24 hours and then kept at 5 
o
C 
for subsequent fluorescence imaging.   
3.3.3   Fluorescence Image Acquisition 
 Gray scale (12-bit) images (1344 × 1044 pixels) of gastrocnemius myofibers were 
acquired with a CCD camera (Orca ER C4742-95; Hamamatsu Photonics, Bridgewater, 
NJ), a Leica microscope (DMRXA2; North Central Instruments, Plymouth, MN) (10× 
objective; 0.5128 µm/pixel), and Image-Pro® Plus software.  Excitation energy was 
delivered with a 150 W HgXe lamp (Hamamatsu Photonics). 
Fluorescence images were collected from a total of 5 different locations (frames) 
on each of two slides per patient.  At each location, images were collected in fluorescence 
channels corresponding to each fluorophore; 1) excitation at 350 nm and emission at 460 
nm (Alexa Fluor 350) and 2) excitation 480 nm and emission at 535 nm (Alexa Fluor 
488).  The images of the sarcolemma (Figure 3.21A) were collected in the 460 nm 
channel and the images of myosin (Figure 3.21B) were collected in the 535 nm channel.  
In total, 20 images were collected for each patient, i.e., 10 images of the myosin signal 
and 10 images of the corresponding sarcolemma signal. 
3.3.4  Image Processing  
 To extract morphometric parameters for each myofiber, the individual myofibers 
were isolated by segmentation of the fluorescence image.  Image segmentation was done 
with a custom algorithm written in MATLAB (R2009a Mathworks Inc. Natic, MA.), 
using thresholding, edge detection, erosion, dilation, and a set of heuristics.  Labeled 
sarcolemma (Figure 3.21A) provided an outline of each myofiber, while labeled myosin 
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(Figure 3.21B) confirmed that a given outline encompassed a myofiber, as opposed to a 
fat cell or any other element of the inter-myofiber space.  Myofibers on the edge of the 
image were omitted from the final binary segmented image, as accurate morphometric 
parameters could not be extracted from only part of fibers.  The final binary segmented 
image preserved the geometry of individual myofibers, as displayed in Figure 3.21C.   
3.3.5   Morphometric Measures 
Multiple morphometric parameters of each myofiber were measured as variables 
that may discriminate PAD and control muscle, and provide an objective grading of 
disease.  The morphometric parameters included: 1) myofiber cross-sectional area, 
calculated as the number of pixels enclosed within a segmented myofiber, 2) lengths of 
major and minor axes of the myofiber, 3) myofiber perimeter, measured as the number of 
pixels on the boundary of the myofiber, and 4) equivalent diameter, defined as the 
diameter of a circle that has the same area as the segmented myofiber region and 
calculated using Equation (3.3). 
 
                   √
   (                 )
 
   (3.3) 
Additional morphometric parameters of each myofiber included three measures of 
roundness given in Equations (3.4), (3.3) and (3.6).  Multiple measures of roundness were 
employed to capture the irregularities and variations of shape and geometry among 
myofibers.  
            
          
          
 
(3.4) 
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Myofiber solidity, defined as the area of the myofiber divided by the area of a 
fitted convex hull, given in Equation (3.7), was measured as well.  A fitted convex hull is 
the smallest convex polygon that can encompass the myofiber.  A polygon is convex if it 
satisfies the criterion that a line segment connecting any two points inside the polygon lie 
entirely within the polygon.  We selected this measure to capture the concavities or lack 
of concavities in the myofibers.  
          
               
                         
 
(3.7) 
Fiber density was defined as the area occupied by the myofibers divided by the area 
occupied by the myofibers plus interstitial tissue, given in Equation (3.8).         
              
              
                                  
 
(3.8) 
 Finally, a quartile analysis was performed on each tissue specimen, by which the 
myofibers were separated into three groups based on cross-sectional fiber area, the lower 
quartile (small fibers) denoted as ‘LQ’, the middle two quartiles (medium size fibers) 
denoted as ‘M50%’, and the upper quartile (larger fibers) denoted as ‘UQ’.  Quartile 
analysis was performed so that morphometric parameters within the lower and upper 
quartiles would not be lost in the average of the global morphometric measurements.  The 
mean and standard deviation of the nine morphometric parameters for all myofibers and 
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for myofibers in quartiles of cross-sectional area (72 variables), in addition to fiber 
density (one variable) were used to represent each patient.  Thus, a total of 73 variables 
for each of the 56 patients were used to build a classification model that discriminates 
PAD and control muscle, and provides an objective grading of disease. 
3.3.6   Discriminant Model Development 
 Control, claudicating, and CLI patients were assigned randomly to training (9, 9, 
and 10 patients, respectively) and validation (10, 9, and 9 patients, respectively) sets.  
Variable contribution analysis and model development were implemented using the 
training data set. A data preprocessing step was performed to check and verify 
discriminant analysis assumptions.  In addition, the multivariate data were standardized 
to remove units and put each variable on the same scale. Variable contribution was 
analyzed using a stepwise selection procedure (Klecka, 1980; Jennrich et al., 1977) in 
SAS 9.2 (The SAS Institute, Cary, NC.).  Stepwise selection uses both forward selection 
and backward elimination procedures while evaluating the contribution of parameters to 
the discriminatory power of the model (Costanza and Afifi, 1979).   
Linear discriminant analysis was used to create rules that discriminate PAD 
patients and controls based on the computed morphometric variables.  The discriminant 
analysis was divided into two stages corresponding to two models.  The first model 
(Model 1) was designed to discriminate patients with CLI from the group of control and 
claudicating (control/claudicating) patients. The second model (Model 2) was designed to 
discriminate control patients from the claudicating patients.   
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  Six morphometric variables were selected for discriminant Model 1, namely, 
solidity of the lower quartile (LQ Solidity), standard deviation of the major axis from the 
lower quartile (LQ Stdev. Major Axis), standard deviation of roundness2 from the global 
measurements (Global Stdev. Roundness2), the standard deviation of roundness3 from 
the middle two quartiles (M50% Stdev. Roundness3), standard deviation of solidity from 
the middle two quartiles (M50% Stdev. Solidity), and fiber density. 
The training of discriminant Model 1 consisted of 10 CLI patients and 18 
control/claudication patients, each from the training data set.  Note that in the training of 
Model 1 the controls and claudicating patients were treated as a single group.  All 
patients that were classified into the control/claudication group by Model 1 were then 
subsequently passed on to the next stage for analysis by Model 2.   
The training of discriminant Model 2 consisted of 9 controls and 9 claudicating 
patients from the training data set.  Three morphometric variables were selected for 
Model 2, namely, the standard deviation of roundness3 (M50% Stdev. Roundness3) from 
the middle two quartiles, roundness1 from the global measurements (Global 
Roundness1), and the standard deviation of solidity from the upper quartile (UQ Stdev. 
Solidity).   
3.4 RESULTS  
 Muscle degeneration in PAD exhibits multiple features that include combinations 
of myofiber atrophy, loss of the normal polygonal myofiber shape, nuclear clumps, 
increased numbers of internal nuclei  fiber vacuolization, target lesions, myofiber 
regeneration, myofiber necrosis, fibrosis and replacement of muscle by adipose tissue.  
Changes from mild (Figure 3.22B) to moderate (Figure 3.22C), to severe (Figure 
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3.22D), degeneration represent a continuous progression in the extent and severity of 
these features.  Our goal is to use linear discriminant analysis of morphometric 
parameters of gastrocnemius specimens to discriminate control (Figure 3.22A), 
claudicating, and CLI patients.  Linear discriminant analysis is a multivariate statistical 
model that seeks to establish a mathematical rule to separate two or more classes from 
each other (Johnson and Wichern, 2007; Anderson, 1984; Fisher, 1936).  Once a 
mathematical rule is derived it can be used to optimally assign new observations into a 
given classification (Johnson and Wichern, 2007). 
Model 1: Linear discriminant Model 1 is given in Equation (3.9). 
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   (3.9) 
The model discriminated CLI patients and control/claudication patients with 100% 
accuracy in the training data set (n=28).  While validating the discriminant rule, with the 
validation data set (n=28), Model 1 was able to accurately classify 8 of 9 CLI patients 
(88.8%) and correctly classified 19 of 19 control/claudicating patients (100%).  Further, 
this model provides a grading index for progression of muscle degeneration among both 
claudicating and CLI patients (Figure 3.23).   
 An independent t-test was used to test for significant differences in group means 
of the standardized variables used in Model 1 (Figure 3.24), within the training data, 
where a p-value < 0.05 was considered significant.  Fiber density was significantly lower 
(P =0.0005) in CLI patients (n=10;  ̅=-0.81; ± S.E.=0.38) compared to 
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controls/claudicating patients (n=18;  ̅=0.45; ± S.E.=0.10).  The ratio of fiber area to the 
area of ‘fibers plus interstitial tissue’, was lower in CLI compared to control/claudication 
myofibers, indicating that the interstitial tissue was thicker in CLI. An example of the 
fiber density of a control muscle tissue sample, is given in Figure 3.25 (panels A, B, and 
C), while, Figure 3.25 (panels D, E, and F) presents an example of the fiber density of a 
CLI muscle sample.  
Standard deviation of Solidity among the middle two quartiles of the fibers was 
significantly lower (P <0.0001) for the controls/claudicating patients (n=18;  ̅=-0.52; ± 
S.E.=0.13) compared to the CLI patients (n=10;  ̅=0.93; ± S.E.=0.31).  Additionally, the 
Solidity of the lower quartile of fibers was significantly higher (P =0.0021) for the 
controls/claudicating patients (n=18;  ̅=0.40; ± S.E.=0.19) compared to the CLI patients 
(n=10;  ̅=-0.73; ± S.E.=0.28).  Both of these measures of solidity indicated that 
control/claudicating patients had myofibers with fewer concavities and more uniform 
solidity compared to CLI patients, as shown in Figure 3.26.  
The standard deviation of global roundness2 was significantly lower (P <0.0001) 
for control/claudicating patients (n=18;  ̅=-0.50; ± S.E.=0.15) compared to CLI patients 
(n=10;  ̅=0.91; ± S.E.=0.26).  Similarly, the standard deviation of Roundness3 from the 
middle two quartiles of fibers was significantly lower (P <0.0001) for 
control/claudicating patients (n=18;  ̅=-0.54; ± S.E.=0.13) compared to CLI patients 
(n=10;  ̅=0.97; ± S.E.=0.27).  Both of these measures of roundness indicated that CLI 
patients had larger variation in roundness of their myofibers.  
Model 2: Linear discriminant Model 2 is given in Equations (3.10). 
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The model separated controls and claudicating patients with 94.4% accuracy in the 
training data set (n=18), in which 8 of 9 controls (88.0%) were correctly classified and 9 
of 9 claudicating patients (100.0%) were correctly classified.  In validating (n=19) 
discriminant Model 2, 8 of 10 controls (80.0%) were correctly classified and 7 of 9 
claudication patients (77.7%) were correctly classified, giving an overall accuracy of 
78.9%.   
In Model 2, the standard deviation of Roundness3 in the middle two quartiles of 
fibers was significantly lower (P =0.0078) for controls (n=9;  ̅=-0.58; ± S.E.=0.30) 
compared to claudicating patients (n=9;  ̅=0.58; ± S.E.=0.23) , shown in Figure 3.27.  
This measure of roundness indicated that claudicating patients had more variation in 
roundness when compared to control patients.  
Combining the results from Models 1 & 2 yielded an overall accuracy of 96.4%, 
for the training set, shown in Table 3.3  and 82.1%, for the validation set, as presented in 
Table 3.4.   
3.5 DISCUSSION 
We have established that there are consistent and quantifiable changes in 
myofiber morphology that reflect the progression of PAD muscle degeneration and offer 
the possibility of an objective index for grading severity of disease within clinical 
classifications, i.e., Fontaine Stage.  Myofiber morphometrics were determined precisely 
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with mathematical equations that incorporated multiple, objectively defined parameters 
including fiber density, roundness, minor and major axes, and solidity.  To the present 
time, morphological studies of PAD muscle have been limited to qualitative 
histopathological assessments and measurements of myofiber cross-sectional area 
(Hedberg et al., 1988; Makitie and Teravainen, 1977; Farinon et al., 1984).   
Currently, PAD is diagnosed and treated primarily on the basis of the patient’s 
clinical presentation and the results of hemodynamic and imaging evaluation of the 
arterial system of the lower limbs (Norgren et al., 2007).  However, a simple histological 
evaluation of skeletal muscle from PAD limbs reveals damage and degeneration and 
suggests that the pathophysiology of PAD is much more complex than a decline of 
hemodynamics (Pipinos et al., 2008a; Pipinos et al., 2008b).  Work from our and other 
laboratories evaluating skeletal muscles from PAD legs demonstrate that the PAD limb, 
overtime, accumulates increasing amounts of injury that can be measured at the 
molecular, biochemical, physiological and histological level (Pipinos et al., 2008a; 
Pipinos et al., 2008b; Pipinos et al., 2008c; Makris et al., 2007).  Likely, this injury is a 
key determinant of leg function, quality of life and clinical prognosis in PAD. As we 
make continuous progress in our understanding of how the leg as end-organ is being 
damaged in PAD, we realize that measures much more specific and sensitive than 
hemodynamic measurements or angiography must be developed in order to quantify 
accurately and in a patient-specific manner the degree and type of degeneration in the 
PAD limb.   
In this study, we have focused on the histology of PAD muscle and have 
developed a discriminant model of myofiber morphometrics, which grades myofiber 
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damage in the gastrocnemius of PAD patients and provides an index of disease severity 
in the end-organ.  This grading index is a robust first step towards quantifying the 
progression of degeneration in the PAD leg. The index is based on discriminant scores of 
claudicating and CLI patients. We propose that the ranges of discriminant scores for both 
claudicating and CLI patients do not represent random variation, but rather systematic 
changes in disease state.  The higher the discriminant score the higher the muscle 
degeneration.  Claudicating patients with higher discriminant scores (Figure 3.23) had 
more myofiber damage similar to that of CLI patients.  The presence of such advanced 
muscle degeneration in patients with claudication may suggest that these patients are 
prone to deteriorate to CLI. Clinicians may therefore consider more aggressive treatment 
for these patients.  Claudicating patients with lower discriminant scores had less myofiber 
damage and may be considered for different treatment.  Similarly, a grading index 
(coupled to clinical findings) may help clinicians choose the CLI patients that may be 
better served by revascularization, amputation or non-operative management (Nehler et 
al., 2003).  It is clear that prospective natural history studies will be necessary to define 
the role of tissue-based indices such as the one presented in this study in the care of 
patients with PAD. 
Among the predictors, within Model 1 (Equation 3.7), fiber density, variation of 
solidity, and roundness, had the most weight in the discriminant model.  Low fiber 
density reflects advanced injury characterized by fibrosis and deposition of adipose 
tissue.  This measurement quantifies the endomysial (in between myofibers) and 
perimysial (around myofascicles) thickening that occurs with increasing muscle damage.  
In normal muscle, the extracellular connective tissue is very thin and the myofibers and 
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myofascicles are in close contact.  Model 2 (Equation 3.8) is essentially made up of 
measures of roundness in various forms.  Solidity is essentially a different measure of 
roundness, which captures concavities or partial u-shapes of the fibers.  Roundness 
appears to represent myofiber degeneration and/or necrosis associated with loss of 
sarcolemmal integrity and characterized by myofiber swelling.  Adenosine triphosphate 
needed to maintain the membrane ion pumps fail, producing changes in the ionic 
composition of the sarcoplasm and an influx of water with subsequent swelling and 
rounding of the fiber.  These important changes are captured in the discriminant scores of 
our morphometric analyses.  
   The model achieved a high level of accuracy (88%) in classifying CLI patients.  
Surprisingly, the one CLI patient that was misclassified was incorrectly classified as a 
control (Table 3.4).  Based on the mathematics alone, the myofiber morphology of this 
CLI patient (i.e. non-standardized Fiber density=0.85; M50% Stdev. Solidity=0.04; 
Global Stdev. Roundess2= 0.08) is more consistent with the morphology of a control 
subject (i.e. Control means of non-standardized Fiber density=0.85; M50% Stdev. 
Solidity=0.03; Global Stdev. Roundenss2=0.05).  This CLI patient’s muscle has not 
degenerated to the extent that the other CLI patients have (i.e. CLI means of non-
standardized Fiber density=0.75; M50% Stdev. Solidity=0.07; Global Stdev. Roundess2= 
0.09).  Upon examination of this biopsy specimen, the morphology appears to be that of a 
control, with a higher fiber density and less variation in roundness and solidity.  This 
suggests that myofiber morphology alone may not provide sufficient sensitivity to 
classify PAD muscle, as a guide for specific treatment of individual patients.  It may be 
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necessary to incorporate another level of measurement to account for patients that have 
normal morphometric indices, but are still CLI.  
Our study has limitations. Our data are observational and identify a correlation 
between discriminant indices of muscle degeneration and disease stage (claudication and 
CLI). However, the data do not establish that the advancing muscle degeneration within a 
clinical stage (claudication or CLI) represents progression of disease. Second, the sample 
set is not large enough to allow determination of the potential contributions of individual 
patient characteristics, such as co-morbid conditions and activity levels, to degree of 
muscle degeneration. Third, the control subjects are not precisely matched with PAD 
patients on the basis of comorbidities, medications and activity levels. We selected a 
control group of similar age and gender composition to the PAD group and included 
patients undergoing lower extremity operations for indications other than PAD. All 
controls were selected to have normal ABIs at rest and after stress and all led sedentary 
lifestyles.    
PAD injury could be more precisely classified with addition of other parameters 
such as, myofiber oxidative damage, inflammatory cytokines, and mitochondrial 
dysfunction.  Development and validation of such a panel of tissue-based biomarkers 
may produce a powerful classification tool which can: 1) more effectively guide the 
treatment of individual patients, with the patients having the most advanced injury being 
treated more aggressively, and 2) allow objective determination, at the tissue level, of the 
outcomes produced by pharmacologic and surgical interventions. In future studies, these 
models which provide scores representing a continuum of myofiber damage may be 
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evaluated on the basis of their ability to predict objective, biomechanical indicators of 
limb function. 
Morphological damage to myofibers can be quantified with small gastrocnemius 
samples obtained with minimally invasive needle biopsy, using discriminant modeling. A 
discriminant model based on myofiber morphometrics has established a correlation 
between advancing muscle degeneration and PAD progression. This model separated 
PAD from control patients and provided a grading of muscle degeneration within clinical 
stages of PAD. The long-term goal of our work is to develop a comprehensive profile of 
quantitative morphometric changes in PAD muscle, which will serve as a guide for more 
extensive mechanisms and intervention studies essential for much needed improvement 
of diagnosis, staging and treatment of PAD.   
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Figure 3.21.  A) The sarcolemma labeling provided an outline of each myofiber. B) The 
myosin labeling served as a confirmation that a given sarcolemma outline encompassed a 
myofiber. C) The final binary segmented image contained the geometry of each 
myofiber.  Note that myofibers on the edge of the image were removed, as accurate 
morphometric parameters could not be extracted from only part of the myofibers. 
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Figure 3.22.   A) Normal muscle with polygonal shaped myofibers that are uniform in 
shape and size, peripherally located nuclei and thin endomysium and perimysium. B) A 
specimen of mildly damaged PAD muscle with evidence of mild myofiber atrophy, the 
presence of rounded or angular atrophic myofibers. C) A specimen of moderately 
damaged PAD muscle with evidence of moderate myofiber atrophy, rounded or angular 
atrophic myofibers, occasional internal nuclei, vacuolization and moderate endomysial 
fibrosis. D) A specimen of moderately damaged PAD muscle with evidence of severe 
myofiber atrophy and enlargement, angular, polygonal or round myofibers, increased 
numbers of internal nuclei, and moderate endomysial and perimysial fibrosis. 
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Figure 3.23.  Patient scores from Model 1 discriminating claudicating patients from CLI 
patients, based on mophometric parameters of their gastrocnemius myofibers.  
Claudicating patients closer to zero have myofiber morphology that is approaching or is 
more similar to the myofiber morphology of CLI patients.  
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Figure 3.24.   Means of standardized selected parameters for Model 1, used to 
discriminate between critical limb ischemia (CLI) and Control/Claudicating patients.   
Values are means ± standard error;  
*Group means were significantly different using a t-test 
*LQ Solidity (P=0.0021) ― (Lower Quartile, i.e. small fibers); 
*Global Stdev. Roundness2 (P<0.0001); 
*M50% Stdev. Roundness3 (P<0.0001) ― (Middle 50%, i.e. medium size fibers); 
*M50% Stdev Solidity (P<0.0001) ― (Middle 50%, i.e. medium size fibers); 
*Fiber Density (P=0.0005); 
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Figure 3.25.  Fiber density was defined as the area occupied by the myofibers divided by 
the area occupied by the myofibers plus interstitial tissue. Panels A & D display myosin 
images, with myofiber segmentation overlaid in green.  Panel B presents the fiber density 
(0.86) of a muscle tissue sample from a control subject, while Panel E presents the fiber 
density (0.70) of a muscle tissue sample from a patient with critical limb ischemia (CLI) 
and severe myopathic changes.  Panels C & F display sarcolemma image, with myofiber 
segmentation overlaid in green.   
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Figure 3.26.  Binary images of segmented myofibers. A) Control.  B) Critical limb 
ischemia (CLI). C) Control middle 50% based on fiber area (M50% Solidity) and fitted 
convex hulls (red).  D) CLI middle 50% based on fiber area and fitted convex hulls (red).  
M50% CLI fibers exhibit higher variation in solidity (i.e. more concavities) compared to 
M50% control fibers.  Arrows identify myofibers with reduced solidity.  
A B 
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Figure 3.27. Means of standardized selected parameters for Model 2, used to 
discriminate between Controls and Claudicating patients.   
*Group means were significantly different using a t-test 
*M50% Stdev. Roundness3 (P=0.0078) ― (Middle 50%, i.e. medium size fibers) 
UQ Stdev. Solidity ― (Upper Quartile, i.e. large fibers) 
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Table 3.2.  Demographics of patients with peripheral arterial disease (PAD) and control 
patients. 
 Control Claudication CLI* 
Number of subjects  19 18 19 
Mean Age (years)  64.6 ± 2.6 60.2 ± 1.9 64.0 ± 2.1 
Gender (male/female) 16/3 17/1 18/1 
Smoking   41.2% 64.7% 78.9% 
Obesity  29.4% 23.5% 10.5% 
Hypertension 64.7% 88.2% 78.9% 
Ankle brachial index (ABI) 1.08 ± 0.02 0.35 ± 0.06 0.27 ± 0.05 
*Critical Limb Ischemia 
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Table 3.3. Combining models 1 & 2 training results, classification table. 
 
 
Predicted Membership Accuracy % 
 
 
Controls  Claudication CLI* Total 
 
Actual 
Membership 
Controls 
 
8 1 0 9 88.8% 
Claudication 0 9 0 9 100.0% 
CLI* 0 0 10 10 100.0% 
 Total 8 10 10 28 96.4% 
*Critical Limb Ischemia 
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Table 3.4. Combining models 1 & 2 validation results, classification table. 
 
 
Predicted Membership Accuracy % 
 
 
Controls  Claudication CLI* Total 
 
Actual 
Membership 
Controls 
 
8 2 0 10 80.0% 
Claudication 2 7 0 9 77.7% 
CLI* 1 0 8 9 88.8% 
 Total 11 9 8 28 82.1% 
*Critical Limb Ischemia 
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4.1 ABSTRACT 
Peripheral arterial disease (PAD) is a vascular disease characterized by stenosis of the 
non-coronary arteries that affects approximately 8 – 10 million Americans. PAD 
produces a progressive accumulation of ischemic injury to the limbs that is reflected in a 
gradual worsening in the microscopic morphology and oxidative stress in the 
gastrocnemius (calf muscle).  The objective of this study was to build a comprehensive 
discriminant model that incorporated morphometric parameters of myofibers, oxidative 
damage in myofibers measured as protein carbonylation, measures of centrally located 
nuclei, and measures of clustering micro-fibers to classifying disease severity of PAD. 
Biopsies were collected from the gastrocnemius with a Bergstom needle from PAD 
patients with claudication (n=19) and critical limb ischemia (CLI; n=20) and control 
patients (n=21).  High resolution tiled images of 24 adjacent frames of the muscle tissue 
specimen were acquired using a 10x objective. The discriminant model, based on 
morphometric and oxidative stress parameters, was able to correctly classify clinical 
stages of PAD and control patients with an overall accuracy of 83.3% using a cross-
validation procedure. Myofiber morphometrics plus oxidative stress parameters provided 
a discriminant model that establishes a correlation between PAD progression and 
advancing muscle degeneration.  This model effectively separated PAD and control 
patients and provided a grading of muscle degeneration within clinical stages of PAD.  
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4.2 INTRODUCTION 
Peripheral arterial disease (PAD) is a vascular disease characterized by stenosis of 
the non-coronary arteries.  It is estimated that PAD affects approximately 8 – 10 million 
Americans (Norgren et al., 2007).  This condition becomes more common as one gets 
older and the number of affected Americans is expected to increase with an increase of 
the elderly population.  In the past, it was presumed that the manifestations of PAD were 
solely due to the atherosclerotic blockages and reduced blood flow to the limbs (Pipinos 
et al., 2008a).  However, the pathophysiology of PAD and its end-organ effects are more 
complex than what can be explained by the mismatch of blood flow and oxygen demand 
(Hirsch et al., 2006).  Literature reports indicate that there is a myopathy that occurs 
secondary to the vascular disease (Pipinos et al., 2008a; Pipinos et al., 2008b; Pipinos et 
al., 2008c).  An increasing number of studies suggest that repeated cycles of ischemia 
followed by reperfusion trigger inflammatory responses, compromise cellular 
bioenergetics, and generate reactive oxygen species (Pipinos et al., 2008a).   
Ambulatory pain caused by inadequate blood flow to the muscles in the lower 
extremities is known as claudication (Hirsch et al., 2006).  Although patients can 
experience leg pain for many other reasons than PAD, a key indicator of PAD is that the 
pain is associated with exercise.  The exercise induced ischemic conditions cause a 
mismatch of oxygen supply and increased demand within the muscle during exercise, 
resulting in cramping, pain, fatigue, and discomfort.  Upon cessation of exercise and 
returning to a resting muscle state, the aching, fatigue, and cramping disappear.  
Ultrastructural and biochemical studies demonstrate that the primary organelle damaged 
in this process is the mitochondrion (McDermott et al., 2004). Dysfunctional 
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mitochondria further lower the already decreased energy levels (associated with 
compromised blood supply) in the pathologic muscle and become sources of increasing 
levels of reactive oxygen species (ROS) and possibly inducers of apoptosis (McDermott 
et al., 2004).  Elevated levels of ROS produce oxidative damage to the muscle.  
As injury accumulates, the patient’s clinical condition deteriorates from being 
asymptomatic to having claudication and then developing critical limb ischemia.  Critical 
limb ischemia (CLI) is an advanced stage of PAD in which, patients experience pain due 
to inadequate blood perfusion while at rest (Hirsch et al., 2006).  This condition often 
produces non-healing foot ulcers and gangrene, and often leads to amputation.  
Progressive accumulation of ischemic injury to the limbs is reflected in a gradual 
worsening in the microscopic morphology of the gastrocnemius (calf muscle).  Normal 
muscle morphology is characterized by polygonal myofibers that are generally uniform in 
shape and size, with thin endomysium and perimysium tissue, and peripherally located 
nuclei.  Moderately myopathic muscle cells generally have an increased variation in 
shape and size and begin to develop fiber vacuolization and target lesion with centrally 
located nuclei.  In severely myopathic myofibers, groups of deteriorating micro-fibers 
begin to appear, with myofiber vacuolization, target lesions, centrally located nuclei, and 
thicker endomysial and perimysial interstitial tissue that is more fibrotic.  Thus, 
morphology of myofibers changes during the progression of PAD.   
In Chapter 3, we have shown that quantitative morphological parameters of 
myofibers in the lower limb musculature, in particular the gastrocnemius, change in a 
consistent and predictable manner during the progression of PAD and provided an 
objective grading of the disease.  The objective of this study is to enhance the 
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discriminant model incorporating new variables, such as oxidative damage measured 
with protein carbonylation, measures of centrally located nuclei, and measures of 
clustering micro-fibers to enhance and create a more comprehensive discriminant model. 
Thus, the specific objectives of this study are 1) to characterize peripheral arterial disease 
by extracting new variables including centrally located nuclei, clustering of micro-fibers, 
and oxidative damage using mechanism-based biomarkers of carbonyl groups, 2) to 
develop and validate a discriminant model using morphological and oxidative stress 
parameters that classify muscles as control, claudication, and CLI. 
4.3 MATERIALS AND METHODS 
4.3.1 Tissue Samples 
The tissue collection protocol was approved by the Institutional Review Board, 
and all subjects gave informed consent.  We recruited 19 patients with clinical diagnosis 
of claudication, 20 patients with clinical diagnosis of critical limb ischemia (CLI), and 21 
controls who did not have PAD.  Demographic information, from these patients, 
including ABI’s, age, gender, and PAD risk factors are given in Table 4.5.  Patient 
muscle biopsies, taken from the gastrocnemius were acquired with a Bergstom needle, 
fixed in methacarn, and embedded in paraffin.  Three 4 µm cross sections, from each 
biopsy, were mounted on slides for image acquisition.       
4.3.2 Fluorescence Labeling of Tissue Sections 
In preparation for labeling sarcolemma, myosin types I and II, protein carbonyls, 
and nuclei the slide specimens were deparaffinized with xylene and rehydrated via a 
series of ethanol washes and distilled water.  The rehydrated slide specimens were then 
transferred to a container with 0.01 M citrate buffer (with 0.05% Tween 20; pH 6.0) and 
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heated in a microwave set to 65 
o
C for 10 minutes for epitope recovery and then allowed 
to cool for 20 minutes.  The slide specimens were soaked in SuperSensitive Wash buffer 
(SS; BioGenex Laboratories, Inc., Freemont, CA) for 30 minutes at room temperature, 
with stirring.  Slides were then prepared for the programmable autostainer by placing a 
lipid barrier on the dried areas around the tissue specimens.  While applying the lipid 
barrier, care was taken to ensure that the tissue specimens were kept moist.   
 A programmable autostainer (BioGenex i6000; BioGenex Laboratories) was used 
to label the sarcolemma, myosin heavy chains, and protein carbonyls.  The slide 
specimens were washed eight times with SS buffer (4 min. per wash) then native 
biotinylation was blocked with avidin (Zymed; Avidin/Biotin blocking kit 00-4303) for 
10 minutes, washed two more times with SS buffer (4 min per wash) then treated with 
biotin to bind all the sites of avidin.  Slide specimens were washed again with SS buffer 
two times (4 min per wash) and treated for 5 minutes with a biotinylation buffer 2-(N-
morpholino)ethanesulfonic acid with a pH 5.5 (MES).  Subsequently, the slides were 
treated with a 5 µM biotinylation solution and incubated at for 1 hour inside a dark slide 
box with double distilled water (DdH2O) in the bottom.  The biotinylation solution was 
prepared from biotin hydrazide (Calibiochem; cat# 203110), dimethylsulfoxide (DMSO; 
Sigma cat# 8418-250ML) and MES solution.  Biotin hydrazide reacts specifically with 
carbonyl groups of aldehydes and keytones, forming hydrozone bonds and converting 
carbonyl groups to biotin groups.  Slide specimens were then placed in a glass container 
filled with phosphate buffered saline (PBS) and stirred with a stir bar for 10 minutes.  
The slides were then placed in a 15 mM cyanoborohydride (Aldrich cat#156159-10G) 
solution and incubated at room temperature for 30 minutes to stabilize the hydrazone 
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bonds.  Slide specimens were then placed in a glass container filled with PBS solution 
and stored overnight in the refrigerator at 5
 o
C.  After overnight incubation, slide 
specimens were loaded into the autostainer and were washed two times with SS buffer (4 
min. per wash) then labeled for 30 minutes with streptavidin coupled with Alexa Fluor 
488 (Life Technologies-Molecular Probes; S32354) which binds to the biotinylated 
carbonyls allowing detection and quantification of protein carbonylation.  The slide 
specimens were washed two times with SS buffer (4 min per wash) then blocked with 
10% goat serum for 20 minutes.  Subsequently, the slides were treated with a mixture of 
anti-Type I myosin (Sigma-Aldrich, St. Louis, MO; M8421, clone NOQ7.5.4D) and anti-
Type II Myosin (Sigma-Aldrich; M4276, clone MY-32) antibodies, for 90 minutes.  
Slides were treated with primary antibody or isotype control for 90 minutes, then washed 
two times with SS buffer (4 min. per wash), followed by a labeling of goat anti-mouse 
IgG Alexa Fluor 594 conjugate (Life Technologies-Molecular Probes; A11032) for 30 
min.  The slide specimens were washed two more times with SS buffer (4 min per wash) 
and then treated for 1 hour with wheat germ agglutinin-Alexa Fluor 647 to label the 
sarcolemma (Life Technologies-Molecular Probes, Grand Island, NY; W11263).  Treated 
slides were washed two times with SS buffer.  Finally, ProLong Gold antifade medium 
with DAPI nuclear stain (Life Technologies-Molecular Probes; P36931) was applied to 
the labeled specimens and covered with a coverslip.  The slides were stored at room 
temperature for 24 hours, sealed with clear lacquer, and then kept at 5 
o
C for subsequent 
fluorescence imaging. 
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4.3.3 Fluorescence Image Acquisition 
Gray scale (12-bit) images (1344 × 1044 pixels) of gastrocnemius myofibers were 
acquired with a CCD camera (Orca ER C4742-95; Hamamatsu Photonics, Bridgewater, 
NJ), a Leica microscope (DMRXA2; North Central Instruments, Plymouth, MN)(10× 
objective; 0.51 µm/pixel), with an automated stage, and Image-Pro® Plus software.  
Excitation energy was delivered with a 150 W HgXe lamp (Hamamatsu Photonics). 
Images were collected from 24 microscope fields (1344 × 1044 pixels) adjacent to 
each other (4 columns × 6 rows) and tiled resulting in a large high-resolution tiled image 
(5376 × 6144 pixels) of each of three slides per patient.  At each field of view, images 
were collected in fluorescence channels corresponding to each fluorophore; 1) excitation 
495 nm and emission at 519 nm (Alexa Fluor 488) for protein carbonylation imaging 
shown in Figure 4.28; 2) excitation at 590 nm and emission at 617 nm (Alexa Fluor 594) 
for myosin types I and II imaging shown in Figure 4.29; 3) excitation at 650 nm and 
emission at 668 nm (Alexa Fluor 647) for imaging the sarcolemma Figure 4.30; and 4) 
excitation at 675 nm and emission at 694 nm (DAPI) for imaging the muscle nuclei, 
shown in Figure 4.31.   
4.3.4 Image Processing 
To extract morphometric parameters for each myofiber and measure protein 
carbonyl content, the individual myofibers were isolated by segmentation of the 
fluorescence image.  Image segmentation was done with a custom algorithm written in 
MATLAB (R2009a Mathworks Inc. Natic, MA.), which was based on simple 
thresholding, edge detection, erosion, dilation, and a set of heuristics.  Labeled 
sarcolemma (Figure 4.30) provided an outline of each myofiber, while labeled myosin 
113 
 
(Figure 4.29) confirmed that a given outline encompassed a myofiber, as opposed to a fat 
cell or other element of the inter-myofiber space.  Myofibers on the edge of the image 
were omitted from the final binary segmented image, as accurate morphometric 
parameters could not be extracted from only part of fibers.  The final binary segmented 
image contained the geometry of each individual myofiber, as displayed in Figure 4.32.   
Figure 4.33 displays a flow chart of the methodology used to segment the 
individual myofibers in the image.  Any errors in image segmentation usually came from 
images that had poor labeling or non-uniform labeling.  Occasionally, the labeled 
sarcolemma did not form a complete boundary around the myofiber.  Likewise, on 
occasion the myosin labeled image had dark areas where the Alexa Fluor did not label 
very well.  So in some cases the myosin labeled image produced a better myofiber 
segmentation and in other cases the sarcolemma image produced better myofiber 
segmentation.  Therefore, to achieve the best automated image segmentation, the 
segmentation process was performed on both the myosin and sarcolemma labeled images 
separately and then presented to a heuristic algorithm that chose the best of each to 
produce a final segmented image.   
4.3.5 Heuristic rules to improve myofiber image segmentation 
Figure 4.34 presents some common image segmentation errors (circled in red) 
that were encountered due to non-uniform labeling of the sarcolemma or myosin.  The 
heuristic algorithm evaluated each individual myofiber from both the myosin 
segmentation and the sarcolemma segmented images and selected the best based on a set 
of heuristic rules that produced the most accurate automated myofiber segmentation. The 
automation of this segmentation process significantly reduced the time that would have 
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been required to manually segment each image, while still preserving accurate myofiber 
segmentation.  In Figure 4.34 the green circled areas, represent the correct segmentation 
and the fibers that were used to build the final segmented image. Red circled areas (in 
Figure 4.34) represent segmentation errors that were recognized by the heuristic 
algorithm and therefore removed from the final segmented image.  Heuristic rule #1 
evaluated whether or not a given object in the sarcolemma image was in fact a myofiber.  
This was done by comparing the pixel value at the same location on the corresponding 
myosin labeled image segmentation.  If there was no myosin present at that location then 
that object in the sarcolemma image was not a myofiber and therefore removed from the 
final segmented image.  Heuristic rule #2 preserved narrow myofibers from being split 
during the erosion and dilation processes.  This type of error usually occurred during 
segmentation of narrow myofibers while using the sarcolemma image.  Hence the rule 
would compare the sarcolemma segmentation with the myosin segmentation, specifically 
looking at myofibers with small minor axes and judge whether or not the narrow fiber 
was erroneously split into two myofibers.  Heuristic rule #3 looked for “joint” myofibers 
that were connected, but should have been separated.  These “joint” fibers were identified 
when one fiber would occupy the same corresponding space of two or more fibers in the 
other segmented image.  If a heavy erosion turned the one fiber into three then it was 
confirmed that it was indeed three fibers, whereas, if one fiber remained as one fiber even 
after performing a heavy erosion then it was confirmed that it was indeed one fiber and 
the other segmented image erroneously produced three segmented fibers.  Based on this 
heuristic, “joint” myofibers were found and removed from the final segmented image.  
Heuristic rule #4 identified fibers that did not segment well during thresholding, due to 
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non-uniform labeling and selected the correctly segmented fiber for the final segmented 
image.  This type of error generally occurred during segmentation with the myosin 
image.  Therefore, based on a measure of solidity and a comparison of the corresponding 
myofiber within the sarcolemma segmented image, poor image segmentation was 
identified and a judgment was made to keep the sarcolemma segmentation for that 
myofiber.  Heuristic rule #5 preserved the shape of smaller fibers, by recognizing that 
with the sarcolemma image small fibers, often were lost during segmentation, and 
therefore these were selected from the segmented, myosin image.  Myofiber image 
segmentation was considerably improved and the time to segment the images was 
significantly reduced by automating the segmentation process, based on these heuristic 
rules.  
4.3.6 Oxidative Damage and Morphometric Measures 
Morphometric variables as well as oxidative damage variables were measured 
from each myofiber and the averages and standard deviations were used as inputs to a 
discriminant model to classify PAD and control muscle.  Protein carbonylation in 
myofibers was measured as the average and standard deviation in pixel value intensity 
from myofiber images captured using quantitative fluorescence microscopy of 
biotinylated carbonyls coupled with fluorphor.  This measure represented oxidative 
damage in the muscle tissue.  In addition, multiple morphometric features, as described in 
Chapter 3, were measured from each myofiber as well.  The morphometric features 
included: 1) myofiber cross-sectional area, calculated as the number of pixels enclosed 
within a segmented myofiber, 2) lengths of major and minor axes of the myofiber, 3) 
myofiber perimeter, measured as the number of pixels on the boundary of the myofiber, 
116 
 
4) equivalent diameter, 5) three measures of roundness (Chapter 3), 6) myofiber solidity, 
defined as the area of the myofiber divided by the area of a fitted convex hull and 7) 
myofiber eccentricity. Eccentricity is a measure of how much a shape deviates from a 
circle and was measured by calculating the ratio of distance between foci, Equation (4.1), 
to major axis, as shown in Equation (4.2).  If the myofiber was a perfect circle the 
eccentricity would equal to zero, whereas, if the myofiber was an elongated ellipse the 
eccentricity approached a value of one.  Fiber density was measured as well, defined as 
the area occupied by the myofibers divided by the area occupied by the myofibers plus 
interstitial tissue, as described in Chapter 3. 
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 (4.1) 
where, x is the major axis and y is the minor axis 
              
                     
          
 
(4.2) 
 Further, clustering of degenerating myofibers was measured as well; using a 
custom density based clustering routine.  The density based clustering routine identified 
fiber clustering by examining the proximity (within 30 pixels of each other) of smaller 
myofibers (fiber area ≤ 4000 pixels), as shown in  
Figure 4.35.  If the fibers that had a fiber area ≤ 4000 pixels were within 30 
pixels of each other, they were grouped as a cluster.  We will refer to these small 
myofibers that appear in clusters of degenerating myofibers as micro-fiber clusters.  
Additional variables were extracted from the micro-fiber cluster analysis, such as; 1) 
number of fibers per cluster, 2) average fiber area per cluster, 3) number of clusters per 
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tissue sample, and 4) the average distance from fiber centroid to cluster centroid was 
calculated.  
Finally, a quartile analysis was performed on each tissue specimen, by which the 
myofibers were separated into three groups based on cross-sectional fiber area, the lower 
quartile (small fibers) denoted as ‘LQ’, the middle two quartiles (medium size fibers) 
denoted as ‘M50%’, and the upper quartile (larger fibers) denoted as ‘UQ’.  Quartile 
analysis was performed so that morphometric features within the lower and upper 
quartiles would not be lost in the average of the global morphometric measurements.  The 
mean and standard deviation of oxidative damage and morphometric variables for all 
myofibers and for myofibers in quartiles of cross-sectional area and fiber density were 
used to represent each patient.  Thus, a total of 93 variables for the 60 patients were used 
to build a classification model that discriminates PAD and control muscle, and provides 
an objective grading of disease. 
 
4.3.7 Data Analysis 
A data preprocessing step was performed in order to check and meet discriminant 
model assumptions.  In addition, the multivariate data were standardized (mean centering 
of each variable followed by normalization by the corresponding standard deviation of 
that variable) to remove units and put each variable on the same scale.  Variable 
contribution was analyzed using a stepwise selection procedure (Klecka, 1980; Jennrich 
et al., 1977) in SAS 9.2 (The SAS Institute, Cary, NC.).  Stepwise selection uses both 
forward selection and backward elimination procedures while evaluating the contribution 
to the discriminatory power of the model (Costanza and Afifi, 1979).   
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Linear discriminant analysis was used to create rules that discriminate PAD 
patients and controls based on morphometric variables.  The discriminant analysis was 
performed in two stages using two models.  The first model (Model 1) was designed to 
discriminate patients with CLI from the group of control and claudicating 
(control/claudicating) patients. The second model (Model 2) was designed to discriminate 
control patients from the claudicating patients.   
  Seven variables were selected for discriminant Model 1, namely, standard 
deviation of the myofiber diameter from the lower quartile (LQ Stdev. Diameter), 
standard deviation of myofiber perimeter from the lower quartile (LQ Stdev. perimeter), 
average myofiber area from myofibers within clusters of micro-fibers (CFA), the standard 
deviation of carbonyl pixel intensities (Stdev. Carbonyl), from the middle two quartiles 
standard deviation of myofiber solidity (M50% Stdev. Solidity), fiber density, and average 
myofiber solidity from the lower quartile (LQ Solidity). 
Model 1 was designed to discriminate CLI patients from the controls and 
claudicating patients.  All samples that were classified into the control/claudication group 
by Model 1 were passed on to the next stage for analysis by Model 2; which 
discriminates control and claudicating patients.  Six morphometric variables were 
selected for Model 2, namely, the global standard deviation of myofiber perimeter (GL 
Stdev. Perimeter), average myofiber solidity from the lower quartile (LQ Solidity), 
average carbonyl pixel intensity, the standard deviation of myofiber major axis from the 
upper quartile (UQ Stdev. Major Axis), standard deviation of myofiber diameter from the 
upper quartile (UQ Stdev. Diameter), and the standard deviation of myofiber eccentricity 
from the upper quartile (UQ Stdev. Eccentricity).  
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4.4 RESULTS AND DISCUSSION 
Figure 3.2 from Chapter 3 exhibit the progressive accumulation of injury to the 
muscle of PAD patients ranging from mild, to moderate, to severe morphometric changes 
in the myofibers.  In this study, we evaluated the hypotheses that morphometric 
determinants and oxidative damage of myofibers, in needle biopsies of the 
gastrocnemius, discriminate PAD patients from controls and quantify disease severity.  
Model 1 is a mathematical rule derived using linear discriminant analysis to separate CLI 
patients from control and claudicating patients. 
Model 1: Linear discriminant Model 1 is given in Equation (4.3). 
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All patients classified into the Control/Claudicating group by Model 1 were then passed 
on to Model 2 which was designed to discriminate between controls and claudicating 
patients.  Model 2 is a mathematical rule derived using linear discriminant analysis to 
separate patients from control and claudicating patients. 
Model 2: Linear discriminant Model 2 is given in Equations (4.4). 
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Model 1 was able to correctly classify 17 of 20 CLI patients yielding an 85.0% accuracy 
and correctly classified 36 out of 40 Control/Claudicating patients using a full cross-
validation procedure.  The 36 patients that Model 1 classified as Control/Claudicating 
were then passed on to Model 2 which was able to correctly classify 18 out of 21 control 
patients (85.7%) and correctly classify 15 out of 15 claudicating patients (100%).  Table 
4.6 combines the classification and misclassification results from both models into a 
confusion matrix.  After combining the results from both models, 85.7% of control 
patients, 78.9% of claudicating patients, and 85.9% of CLI patients were correctly 
classified yielding an overall accuracy of 83.3%. 
 An independent t-test was used to test for significant differences in group means 
of the standardized variables used in Model 1 (Figure 4.36), where a p-value < 0.05 was 
considered significant.  Again, as was found in the earlier study performed in Chapter 3, 
Fiber density, M50% Stedev. Solidity, and LQ Solidity were all found to be significantly 
different between CLI patients and controls/claudicating patients with p-values of 
P=0.0017, P=0.0039, and P=0.0195 respectively.  These results indicate that CLI patients 
have lower fiber density, higher variation in solidity within medium size fibers, and are 
less solid within smaller fibers when compared to control and claudicating patients.  Note 
that the previous study performed in Chapter 3 had a smaller data set of approximately 
15,000 myofibers, while this current data set was about 5 times larger, examining 
approximately 165,000 myofibers.  Further, in this larger data set new variables including 
oxidative damage measurements, centrally located nuclei, and micro-fiber clustering 
were incorporated as well.  Thus, using this larger data set additional new morphometric 
parameters were found to be useful in rebuilding the discriminant model, while some of 
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the variables found in Chapter 3 were no longer included in the model.  New parameters 
found to be important for this model included LQ Stdev. Diameter, LQ Stdev. Perimeter, 
and average fiber area among micro-fiber clusters (CFA) with p-values P<0.0001, 
P=0.0012, and P<0.0001 respectively.  These variables reveal that CLI patients have less 
variation in diameter and perimeter among smaller fibers (i.e. lower quartile). These 
results make sense, as CLI patients tend to have more degenerating myofibers and 
degenerating myofibers tend to fall into the lower quartile in terms of fiber area.  
Therefore, the small degenerating myofibers were usually round and more uniform.  
Further, CLI patients had more micro-fiber clustering than control and claudication 
patients.  Note, in the earlier study (Chapter 3) micro-fiber clustering was measured as 
well, but not selected by the model.  This suggests that the low-resolution images (i.e. 
randomly captured images from 5 locations on the tissue specimen) was not able to pick 
up micro-fiber clustering effectively.  Whereas, within this study the high-resolution tiled 
images were able to effectively capture this variable.  Another variable of importance was 
the variation of oxidative damage (Carbonyl Stdev.) with a p-value of P=0.0531 was very 
close to the significant level and thus was still an important variable.  This measure of 
oxidative damage to the muscle suggested that CLI patients have a larger variation of 
protein carbonylation compared to control and claudicating patients.    
 In Model 2, which was designed to discriminate claudicating and control patients, 
the Global Stdev. Perimeter and UQ Stdev. Diameter were significantly different between 
control and claudicating patients with p-values of P=0.0356 and P=0.0422 respectively.  
In general, control patients had a higher variation in perimeter globally and higher 
variation in diameter among the larger fibers than claudicating patients.   
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Among the predictors in Model 1, variation in the diameter of small fibers (LQ 
Stdev. Diameter), variation in the perimeter of smaller fibers (LQ Stdev. Perimeter), 
clustering of micro-fibers (CFA), and variation in protein carbonyls (Stdev. Carbonyl) 
had the most influence in the model, based on the coefficients in the model.  Lower 
values in the variables LQ Stdev. Diameter and LQ Stedev. Perimeter in CLI patients 
indicate that smaller degenerating myofibers are more consistent in diameter and 
perimeter than the smaller myofibers found in control and claudicating patients.  Higher 
CFA measures in CLI patients reflect increased levels of localized clustering of 
neighboring, small degenerating myofibers which is sometimes referred to as group 
atrophy.  Higher variation in protein carbonyls (Stdev. Carbonyl) reflects more oxidative 
damage in CLI patients and is in agreement with previous research (Pipinos et al., 2008a) 
demonstrating that PAD muscle has mitochondrial dysfunction.  Variables with the 
greatest influence in Model 2 included variation in the major axis of the larger fibers (UQ 
Stdev. Major Axis), variation in perimeter as a global measurement (Global Stdev. 
Perimeter), and variation in solidity of smaller fibers (LQ Solidity).   
This study used morphometric determinants and biochemical (mechanisms-based 
biomarker expressions of oxidative stress) of myofibers, in needle biopsies of the 
gastrocnemius, to build a more comprehensive discriminant model.  The discriminant 
model, based on the morphometrics and oxidative stress in muscle tissue, was able to 
discriminate clinical stages of PAD and controls with an overall accuracy of 83.3%.  
When compared to the results obtained in Chapter 3, which was able to classify clinical 
stages of PAD and control patients with 82.1% accuracy, the results are repeatable.  
However, there are some noticeable differences in the selected variables between the 
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model developed in this study compared to the model created in Chapter 3.  Likely the 
model created in this study is a more complete and accurate representation of the muscle 
damage in PAD patients.  The model created in Chapter 3 was performed on a much 
smaller data set sampled from 5 regions of the muscle tissue that were selected manually, 
whereas the model created in this study was built on a larger data set of high resolution 
tiled images incorporating large portions of the muscle tissue.  Further, the model in this 
study incorporated oxidative stress variables.   
4.5 CONCLUSION 
PAD produces a progressive accumulation of ischemic injury to the limbs. This 
ischemic injury is reflected in a gradual worsening in the microscopic morphology and 
oxidative stress in the gastrocnemius (calf muscle).  The discriminant model, based on 
morphometric and oxidative stress parameters, was able to correctly classify clinical 
stages of PAD and control patients with an overall accuracy of 83.3% using a cross-
validation procedure.  When compared to the previous study carried out in Chapter 3 
these methods for quantifying muscle damage appear repeatable.  However, the model 
created in this study is likely the more complete model that included biochemical 
oxidative damage and morphological parameters.  The discriminant model may be used 
as a complimentary tool to traditional diagnosis/monitoring criterion, providing objective 
criteria for therapeutic interventions.  The ability to quantify oxidative stress and 
characterize the extent of muscle damage due to the disease may provide physicians with 
objective measures to diagnose, monitor muscle degeneration, and aid in the development 
of patient-specific treatments. 
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Figure 4.28.  Protein carbonyl labeled image. High resolution tiled image (5376 × 6144 
pixels)  of ~1000 myofibers. Spatial calibration reference bar is 200 µm.   
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Figure 4.29. Myosin labeled image. High resolution tiled image (5376 × 6144 pixels)  of 
~1000 myofibers. Spatial calibration reference bar is 200 µm.   
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Figure 4.30. Sarcolemma labeled image.  High resolution tiled image (5376 × 6144 
pixels)  of ~1000 myofibers. Spatial calibration reference bar is 200 µm.   
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Figure 4.31. Myofiber nuclei labeled image.  High resolution tiled image (5376 × 6144 
pixels) of nuclei from ~1000 myofibers. Spatial calibration reference bar is 200 µm.   
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Figure 4.32. Binary myofiber segmentation image.  High resolution tiled image (5376 × 
6144 pixels) of ~1000 segmented myofibers.   
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Figure 4.33.  Flow chart of myofiber segmentation process using both myosin labeled 
image and sarcolemma labeled image.   
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Figure 4.34.  Examples of myofiber segmentation errors and heuristic rules used to 
improve automated myofiber segmentation. Green circled areas represent the correct 
segmentation and the fibers that were used to build the final segmented image. Red 
circled areas represent segmentation errors that were recognized by the heuristic 
algorithm and therefore removed from the final segmented image. 1) Not a myofiber 
check, 2) Split narrow myofibers check, 3) Joint myofibers check, 4) Poor segmentation 
due to non-uniform labeling check, 5) Preserve shape of small fibers during erosion and 
dilation check. 
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Figure 4.35.  Micro-fiber clustering or group atrophy events were identified using a 
density based clustering routine and statistical measures were acquired to quantify 
clustering of small degenerating myofibers. 
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Figure 4.36.  Means of standardized selected variables for Model 1, used to discriminate 
between critical limb ischemia (CLI) patients from Control and Claudicating patients.  
Values are standardized group means ± standard error 
*Group means were significantly different using a t-test 
*LQ Stdev. Diameter (P<0.0001) – (Lower Quartile, i.e. small fibers); 
*LQ Stdev. Perimeter (P=0.0012); 
*CFA (P<0.0001) – (average cluster fiber area); 
  Carbonyl Stdev. (P=0.0531); 
*M50% Stdev. Solidity (P=0.0039) – (Middle 50%, i.e. medium size fibers) 
*Fiber Density (P=0.0017); 
*LQ Solidity (P=0.0195); 
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Figure 4.37.  Means of standardized selected parameters for Model 2, used to 
discriminate between Controls and Claudicating patients.   
*Group means were significantly different using a t-test 
*Global Stdev. Perimeter (P=)  
*UQ Eccentricity ― (Upper Quartile, i.e. large fibers) 
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Table 4.5.  Demographics of patients with peripheral arterial disease (PAD) and control 
patients. 
 
Control Claudication CLI 
Number of subjects  21 19 20 
Mean Age (years)  63.8±11.1   63.2±8.7   61.5±7.0  
Gender (male/female) 17/4 19/0 18/2 
 
 
 
Table 4.6.  Discriminant model classification table cross-validation results. 
  Predicted Membership Accuracy % 
 
 Controls  Claudication CLI* Total 
 
Actual 
Membership 
Controls 
 
18 3 0 21 85.7% 
Claudication 0 15 4 19 78.9% 
CLI 0 3 17 20 85.0% 
 Total 18 21 21 60 83.3% 
* Critical Limb Ischemia  
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5.1 ABSTRACT  
Peripheral arterial disease (PAD), characterized by abnormal narrowing of the non-
coronary arteries, produces a considerable public health burden.  PAD produces a 
progressive accumulation of ischemic injury to the lower limbs that is reflected in altered 
metabolic processes, damaged organelles, and compromised bioenergetics.  The objective 
of this study was to correlate PAD patient blood flow (Ankle Brachial Index) with Raman 
spectral signatures of their muscle biochemistry and identify spectral biomarkers that 
characterize muscle damage.  We collected muscle tissue biopsies of the gastrocnemius 
(calf muscle) from 5 patients with clinically diagnosed critical limb ischemia (CLI), 5 
patients with clinically diagnosed claudication, and 5 control patients who did not have 
PAD. A partial least squares regression (PLSR) model was able to predict patient ABI’s 
with a correlation coefficient of 0.99 during training and a correlation coefficient of 0.85 
using a full cross-validation.  When using the first three PLS factor scores in combination 
with linear discriminant analysis, the discriminant model was able to correctly classify 
the control, claudicating, and CLI patients with 100% accuracy, using a full cross 
validation procedure.  In this study we have demonstrated that Raman spectroscopy can 
be a powerful bioanalytical tool that is capable of detecting and correlating biochemical 
composition with patient ABI’s and discriminating PAD clinical diagnosis.  Raman shifts 
that are related to muscle biochemistry and patient ABI’s have been identified.  Raman 
spectroscopy provides novel spectral biomarkers the may complement existing diagnosis 
and treatment monitoring methods for peripheral arterial disease.   
Keywords:  Raman spectroscopy; Peripheral arterial disease; Partial least squares 
regression; Linear discriminant analysis; Muscle biochemistry  
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5.2 INTRODUCTION 
Peripheral arterial disease (PAD), characterized by abnormal narrowing of the 
non-coronary arteries, produces a considerable public health burden affecting 12% to 
20% of Americans above the age 65 (Mahoney et al., 2010; Mahoney et al., 2008; Roger 
et al., 2011).  The pathophysiology of PAD is complex and involves changes occurring 
on multiple levels, such as reduced blood flow, altered metabolic processes, and skeletal 
muscle degeneration (Pipinos et al., 2008b; Pipinos et al., 2008c; Hedberg et al., 1988; 
Marbini et al., 1986).  PAD produces a progressive accumulation of ischemic injury to 
the lower limbs that is reflected in a gradual worsening in the microscopic morphology of 
the gastrocnemius (Hedberg et al., 1988; Pipinos et al., 2008a).  Limb hemodynamics, 
such as Ankle Brachial Index (ABI) is the current gold standard in diagnosing and 
monitoring treatment interventions of PAD.  ABI’s are measured as the ratio of systolic 
pressure in the ankle to that in that in the arm.  Occlusions of the arteries supplying 
oxygen to the legs cause low ankle blood pressure and yielding a low ABI which is the 
clinical hallmark of PAD.  The presence of PAD is defined by ABI values of < 0.90, with 
values 0.90 – 1.0 considered in the normal range.  Other advanced methods such as, 
ultrasonography, venous plethysmography, angiography (x-ray) or (MRA), have been 
employed to characterize PAD based on monitoring blood flow.  However, all these 
methods have limitations in monitoring progression and regression of PAD because there 
is a need to measure more than just abnormal blood flow.  There is a fundamental gap in 
monitoring muscle degeneration progression and regression before and after vascular 
reperfusion surgeries. It is also critical to measure the skeletal muscle effects (i.e. 
myopathy) due to atherosclerosis in addition to measuring the blood flow (Kramer, 
2007).   
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Recent ultrastructural and biochemical studies have begun to characterize the 
myopathy that occurs secondary to the vascular disease.  These studies have 
demonstrated that repeated cycles of ischemia followed by reperfusion, occurring with 
basic daily activities, initiate inflammatory pathways and induce the generation of 
reactive oxygen species (ROS) in the PAD muscle, causing oxidative damage 
(McDermott et al., 2004).   
Raman spectroscopy is a label-free analytical tool that uses the scattering 
properties of light to characterize molecular vibrations within a tissue sample, producing 
a molecular fingerprint.  Raman spectroscopy provides information-rich molecular 
profiles and has potentially important clinical applications for real-time in situ evaluation 
of living tissues (Hanlon et al., 2000).  Raman spectral analysis has been conducted to 
characterize several diseases in biological tissues, including, bronchial tissue, brain 
tissue, stomach ulcers, and breast tissue (Bonifacia et al., 2010; Nijssen et al., 2002; 
Koljenovic et al., 2004; Kirsch et al., 2010).  Other investigations have demonstrated that 
Raman spectroscopy is capable of identifying and constructing chemical maps of 
subcellular structures such as, the nucleus, cytoplasm, and mitochondria (Miljković et al., 
2010; Bonnier et al., 2010).  Applications of Raman spectroscopy have been further 
broadened by making use of metallic nanostructured surfaces to increase the Raman 
scattering signal by multi-fold, referred to as surface-enhanced Raman spectroscopy 
(SERS) (Blackie et al., 2009).  
The objective of this study is to correlate patient blood flow (determined as ABI) 
with Raman spectral signatures of their muscle and identify spectral biomarkers that 
characterize altered muscle biochemistry in patients with PAD.  Our central hypothesis is 
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that surface-enhanced Raman spectroscopy (SERS) signatures from human biopsy 
samples (gastrocnemius muscle) mounted on a nanostructured gold-slide can be used to 
predict patient ABIs and characterize the muscle damage caused by PAD. The rationale 
that underlies this research is that a molecular profile which correlates with ABI and 
clinical stages of disease may provide useful biochemical information to identify factors 
that may regulate or may be precursors to muscle damage and may facilitate the 
development of treatment interventions in human muscle repair.  
5.3 MATERIALS AND METHODS 
5.3.1 Tissue Samples 
The tissue collection protocol was approved by the Institutional Review Board, 
and all subjects gave informed consent.  We collected muscle tissue biopsies of the 
gastrocnemius (calf muscle) from 5 patients with clinically diagnosed critical limb 
ischemia (CLI; ABI<0.4), 5 patients with clinically diagnosed claudication (0.4 ≤ ABI ≤ 
0.9), and 5 control patients (ABI>.9) who did not have PAD.  Demographic information, 
from these patients, including ABI’s, age, gender, and PAD risk factors are given in 
Table 5.7.  The biopsies were acquired with a Bergstom needle, fixed in methacarn, and 
embedded in paraffin.  Two 4µm cross sections, from each biopsy, were mounted on 
slides for Raman spectra acquisition.  Prior to Raman spectra acquisition, the slide 
specimens were deparaffinized with xylene and a series of ethanol washes and allowed to 
air dry.     
5.3.2 Surface Enhanced Raman Spectroscopy (SERS) 
All tissue specimens were mounted on nanostrucutured gold slides 
(AU.1000.ALSI; Platypus Technologies, Madison, WI.) for surface enhanced Raman 
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spectroscopy.  Additionally, 2 control and 2 PAD tissue specimens were mounted on 
glass slides for comparison to the SERS signal.  The inVia Raman microscope 
(Renishaw, Gloucestershire, UK) spectral imaging system was used to acquire Raman 
spectra and surfaced-enhanced Raman spectra of human muscle biopsy specimens.  This 
system is a high-sensitivity research grade system that supports multiple excitation lasers 
and allows acquisition of information-rich spectral images.   
Raman spectral signatures were collected within the finger print region (303 − 
1901 cm
-1
) using a 514 nm excitation laser, with a 50X magnification objective.  The 
tissue was photo-bleached for 60 seconds and then the spectrum was collected with a 10 
second exposure time.  From each tissue specimen, approximately 10 spectra were 
collected from 10 individual myofibers and then averaged (after data preprocessing) to 
represent the tissue specimen.   
5.3.3 Data preprocessing 
Data preprocessing of the raw surface-enhanced Raman spectra included baseline 
correction and normalization techniques.  The Raman spectra were baseline corrected 
using the Vancouver Raman algorithm (Zhao et al., 2007) with a five point boxcar 
smoothing and a 5
th
 order polynomial fit, shown in Figure 5.38.  The Vancouver Raman 
algorithm is a robust iterative modified multi-polynomial fitting algorithm that removes 
intrinsic autofluorescence background signals and improves signal to noise ratios (Zhao 
et al., 2007; Lieber and Mahadevan-Jansen, 2003; Beier and Berger, 2009; Afseth et al., 
2006).  Following baseline correction, the spectra were normalized using the standard 
normal variate (SNV) technique.  SNV normalization is a common mathematical 
transformation for spectral data and is designed to remove multiplicative error and 
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preserve the linear relationship between the spectral signal and sample concentration 
(Rinnan et al., 2009; Barnes et al., 1989).    
5.3.4 Model development 
A partial least squares regression (PLSR) model was developed using the entire 
spectral region from 303 cm
-1
 − 1901 cm-1 to predict patient ABI.  The PLSR algorithm 
combines techniques used in principal component analysis (PCA) and multiple linear 
regression and attempts to quantify the strength of the relationship between the response 
variable and a set of predictor variables (Geladi and Kowalski, 1986).  PLSR searches for 
principal components (called factors) that are orthogonal to each other and tries to relate 
them to the response variable.  The variation present in the response variable can be 
summarized into a few PLS factors.  The first PLS factors that explain the most variance 
in the data can then be used to build a regression model.  An analysis of the β-coefficients 
on the partial least squares regression model can identify which variables had the most 
weight in the predictive PLSR model.  A full cross validation procedure was performed 
on the data set to evaluate the performance of the predictive model.  
In addition to the PLSR model, a discriminant model was developed as well using 
the PLS factor scores from the PLSR model to classify patient’s as control, claudicating, 
or CLI.  The use of discriminant analysis in combination with PLS factor scores is a 
common multivariate statistical method to establish a mathematical rule that separates 
two or more classes from each other (Anderson, 1984; Fisher, 1936).  Once the 
discriminant model has been derived it can be used to classify new observations (Johnson 
and Wichern, 2007).  The discriminant model performance was evaluated with a full 
cross validation procedure as well.       
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5.4 RESULTS 
5.4.1 Surface enhanced Raman spectroscopy 
Figure 5.39 demonstrates the difference between standard Raman spectroscopy 
(n=143 myofibers mounted on glass slides from 2 control and 2 PAD tissue specimens) 
and surface-enhanced Raman spectroscopy (n=150 myofibers mounted on nanostructured 
gold-slides from 2 control and 2 PAD tissue specimens).  The Raman Effect deals with 
the inelastic scattering of light, resulting in a scattered photon that has a shift in frequency 
from the excitation laser.  In general, Raman scattering produces a very weak signal due 
to the fact that only a small fraction, approximately 1 in 10 million, of photons will 
exhibit the Raman Effect.  Surface enhanced Raman spectroscopy (SERS) is a surface 
sensitive technique that can enhance the Raman signal by 10 fold (Blackie et al., 2009).  
From Figure 5.39 it is readily apparent that surface-enhanced Raman spectroscopy 
(SERS) enhances the spectral signature of myofibers mounted on nanostructured gold-
slides when compared to myofibers mounted on glass slides.  The tissue mounted on the 
nanostructured gold-slides produced sharper and more intense Raman peaks.  Hence 
further analyses were performed based on tissue specimens mounted on gold-slides for 
surface-enhanced Raman spectroscopy. 
5.4.2 Partial least squares regression and discriminant analysis 
Figure 5.40 presents the averaged baseline-corrected SNV SERS for control, 
claudicating, and CLI patient specimens, which were used to develop the PLSR model. 
Nearly all of the variance (99%) in the response variable (patient ABI) was accounted for 
by the first six PLS factors, as shown in Figure 5.41.  Using the first six PLS factors, the 
PLSR model was trained and the predictive performance was evaluated using a full cross-
146 
 
validation procedure.  The PLSR model was able to predict patient ABIs with a 
correlation coefficient of 0.99 during training and a correlation coefficient of 0.85 using a 
full cross-validation, show in Figure 5.42.  The β-coefficients for the PLSR model are 
presented in Figure 5.43, which can be used to identify key wavenumbers that influence 
the PLSR model.   
 Further, a plot of the first three PLS factor scores (Figure 5.44) displays clear 
separation of controls, claudicating, and CLI patients.  When using the first three PLS 
factor scores in combination with linear discriminant analysis a discriminant model is 
able to correctly classify the control, claudicating, and CLI patients with 100% accuracy.  
Evaluating the discriminant model performance and stability using a cross-validation 
procedure also yielded 100% accuracy in patient classification.  Table 5.8 presents the 
classification table for the discriminant model cross validation results.  The combination 
of PLS factors 1 and 2 (Figure 5.44A) clearly group and separate control patients from 
claudicating and CLI patients, while, PLS factor 3 (Figure 5.44B) clearly separates 
claudicating patients from CLI patients.    
5.5 DISCUSSION 
 Raman spectroscopy is a powerful noninvasive, optical tool capable of detecting 
biochemical composition within biological tissue, without the use of labeling procedures.  
In this study, we have demonstrated that Raman spectroscopy is capable of predicting 
patient ABIs based on the biochemical fingerprint of PAD muscle tissue.  The PLSR 
model was able to correlate Raman spectral information with patient ABIs with a high 
level of correlation (R-value=0.85).  Moreover, when combining PLS factor scores with 
discriminant analysis the model is able to correctly classify patients with 100% accuracy.  
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To our knowledge, this is the first study to produce a Raman spectral profile of human 
PAD muscle tissue.  Further, very few studies, using other techniques, have been able to 
correlate patient ABIs with biochemical or limb functional parameters. This study is 
novel because it characterizes PAD muscle biochemistry and correlates it to patient 
ABI’s in a manner that has never been done before.   
An examination of the PLS regression β-coefficients (Figure 5.43) gives an 
indication of which wavenumbers had the most important impact on predicting patient 
ABIs.  From Figure 5.43, it can be seen that wavenumbers 519, 524, 718-722, 752-755, 
and 1179 cm
-1
 had the largest beta coefficients and thus indicate that these are key Raman 
spectral bands that reflect the patient ABIs.  The band occurring at 519 cm
-1
 was 
attributed to phosphatidylinositol, a phospholipid component of the cell membrane of 
eukaryotic cells (Movasaghi et al., 2007; Lakshimi et al., 2002).  On average, this band 
had a higher intensity for CLI patients than control patients and a negative relationship 
with ABIs. The band appearing at 524 cm
-1
 was assigned to both the S-S disulfide 
stretching in proteins and phosphatidylserine (Movasaghi et al., 2007; Stone et al., 2004).  
Phosphatidylserine is also a phospholipid component of the cell membrane that is usually 
present on the inner leaflet of the bilayer, but becomes exposed at the cell surface during 
apoptosis (Verhoven et al., 1995).  On average, this band had a higher intensity for CLI 
patients than controls and may indicate higher levels of apoptosis occurring in advanced 
stages of muscle degeneration.  The 718 cm
-1
 band correlates with C-N vibrational 
stretching in phosphatidylcholine lipid heads, which appear in ample amounts in 
mitochondrial membranes (Movasaghi et al., 2007; Alberts et al., 2007; Stone et al., 
2002).  This band had a higher intensity in PAD patients compared to control patients and 
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may be indicative of higher mitochondrial content.  Other PAD biochemical studies have 
also reported elevated levels of mitochondrial content and mitochondrial dysfunction that 
result in compromised bioenergetics in PAD patients (Pipinos et al., 2008b).  However, it 
should be noted that phosphatidylcholine is not just present in mitochondria and appears 
in many other locations as well.  Therefore, the increased intensity in this band may also 
indicate possible accumulations of debris or could be due to target lesions which may 
have elevated levels of membranes.  The 752 cm
-1
 band was attributed to porphyrin 
breathing mode, and is a direct measure of heme groups from hemoglobins providing an 
informative status of red blood cells (Movasaghi et al., 2007; Deng et al., 2005).  This 
band may be reflecting the reduced blood flow in the lower limb musculature caused by 
stenosis of the arteries in PAD patients.     
Other prominent bands occurring at 1546 cm
-1
 and 1688 cm
-1
 were attributed to 
the reduced form of nicotinamide adenine dinucleotide (NADH) (Deng, 1989).  The 
Raman scattering bands occurring at 1032 cm
-1
 was attributed to the oxidized form of 
NAD
+
 (Yue, 1986).  Cellular respiration studies indicate that increased production of 
reactive oxygen species (ROS) result in the oxidation of NADH to NAD
+
 (Zuo and 
Clanton, 2005; Sriramoju et al., 2008).  NADH is an essential coenzyme, within the 
mitochondria, that plays a critical role during the oxidative phosphorylation process.  
Based on the Raman spectra (Figure 5.40), controls had higher intensities in NADH 
bands (1546 and 1688 cm
-1
) compared to PAD patients.  This suggests that PAD patients 
have reduced levels of NADH and increased levels of NAD
+
.  This band could be used as 
a Raman spectral biomarker of oxidative stress in PAD muscle tissue.   
149 
 
 Raman scattering band observed at 1602 cm
-1
 has been associated with human 
mitochondria (Huang, 2004; Pully and Otto, 2009).  Figure 5.40, shows that PAD 
patients have a higher 1602 cm
-1
 band than control patients and suggests higher 
mitochondrial content in PAD patients.  Again this is in agreement with other PAD 
studies that have demonstrated that PAD patients have significantly increased levels of 
mitochondrial content (Pipinos et al., 2008d; Brass and Hiatt, 2000). Although there is an 
increase in mitochondrial content in PAD muscle, respiration or oxidative 
phosphorylation is still lower when compared to the controls due to mitochondrial 
dysfunction (Pipinos et al., 2008d).  Mitochondrial dysfunction can produce reactive 
oxygen species, which in turn could damage the phospholipid mitochondrial wall.      
 Although this study presents spectral biomarkers that are in agreement and are 
explained by other PAD studies, this study does have limitations.  This study was 
performed using a small sample set of only 15 patients.  The results presented in this 
study should be further validated with a larger data set.  In addition, the Raman spectral 
signal is a complicated mixed biochemical profile that can be hard to interpret.   
Researchers have developed Raman spectral libraries of biological tissue to aid in the 
interpretation of Raman spectra (Movasaghi et al., 2007).  However, the interpretation 
should be validated with controlled studies that vary concentration of the molecule and 
validate that the spectral peak changes accordingly.  Therefore, further biochemical 
analysis should be performed to isolate and validate the presence of the suspected 
biochemical profile of PAD muscle tissue.  
In this study we have demonstrated that Raman spectroscopy can be a powerful 
bioanalytical tool that is capable of detecting and correlating biochemical composition 
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with patient ABIs and discriminating PAD clinical diagnosis.   Raman spectroscopy 
provides novel spectral biomarkers the may complement existing diagnosis and treatment 
monitoring methods of peripheral arterial disease (PAD).  Identification of these spectral 
biomarkers may lead to novel disease progression tracking techniques by providing 
information that reflects the underlying pathophysiology and allows the development of 
individualized therapy.  The long-term goal of this research is the quantification of PAD 
muscle degeneration progression or regression in vivo and in situ, as that would have the 
greatest impact on disease management, facilitating patient specific care. 
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Figure 5.38.  A) Raman spectra were baseline corrected using a 5
th
 order polynomial 
with the Vancouver Raman Algorithm.  B) The extracted Raman signal after baseline 
correction.  
 
 
Figure 5.39.  Surface-enhanced Raman spectroscopy (SERS) enhances the spectral 
signature of myofibers mounted on nanostructured gold-slides when compared to 
myofibers mounted on glass slides. 
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Figure 5.40.  Average control, claudicating, and CLI patient SERS.  
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Figure 5.41.   Eigenvalues of partial least squares factors.  The first six PLS factors 
account for most of the variance (>75%).   
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Figure 5.42.  Partial least squares regression model using six PLS factors was able to 
predict patient ABIs with a correlation coefficient of 0.99 and 0.85 in training and full 
cross validation, respectively.   
  
0
0.2
0.4
0.6
0.8
1
1.2
1.4
0 0.2 0.4 0.6 0.8 1 1.2
P
re
d
ic
te
d
 A
B
I 
Actual ABI 
Training
Cross-Validation
Linear (Training)
Linear (Cross-
Validation)
R=0.99 
R=0.85 
155 
 
 
Figure 5.43.  Partial least squares regression β coefficients.  
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Figure 5.44.  PLS factor scores plot.  A) PLS 1 and 2 grouped and separated control 
patients from claudicating and CLI patients.  B) PLS 1 and 3 separated claudicating and 
CLI patients.  These three PLS factors in a discriminant analysis with cross validation, 
classified patients with 100% accuracy.    
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Table 5.7.  Demographics of patients with peripheral arterial disease and control patients. 
 
Control  Claudication  CLI 
Number of subjects  5 5 5 
Mean Age (years) ± Std. deviation  63.2 ± 6.02 67.8 ± 9.58 58.4 ± 2.82 
Ankle brachial index (ABI) 1.06 ± 0.03 0.55 ± 0.03 0.19 ± 0.06 
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Table 5.8.  Patient classification with a discriminant model and cross validation results.  
  Predicted Membership Accuracy % 
 
 Controls  Claudication CLI Total 
 
Actual 
Membership 
Controls 
 
5 0 0 5 100% 
Claudication 0 5 0 5 100% 
CLI 0 0 5 5 100% 
 Total 5 5 10 15 100% 
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CHAPTER 6 :  SUMMARY AND RECOMMENDATIONS FOR FUTURE 
RESEARCH 
 
6.1 SUMMARY 
Peripheral arterial disease (PAD) is a vascular disease characterized by stenosis of 
the non-coronary arteries caused by fatty deposits and plaque buildup, known as 
atherosclerosis (Hirsch et al., 2006).  It is estimated that PAD affects approximately 8-10 
million Americans and produces a considerable public health burden (Norgren et al., 
2007; Hiatt et al., 1995).  PAD is a slowly progressive disease that develops over many 
years and becomes more common as one gets older.  The number of affected Americans 
is expected to increase as the population of elderly persons continues to increase 
(Feinglass et al., 1999; Allison et al., 2007).  The pathophysiology of PAD is complex and 
involves changes occurring on multiple levels, such as reduced blood flow, altered 
metabolic processes, and skeletal muscle degeneration.  PAD affects a large range of 
arterial beds, with most occlusions occurring in the arteries of the legs, pelvis, and 
abdominal aorta causing reduced blood flow to the lower extremities.  In the past it was 
presumed that the manifestations of PAD were solely due to the atherosclerotic blockages 
and reduced blood flow to the limbs.  However, the end-organ effects, due to PAD, are 
more complex than what can be explained by the mismatch of blood flow and oxygen 
demand (Hirsch et al., 2006).  There is a myopathy that occurs secondary to the vascular 
disease producing progressive accumulation of ischemic injury to the lower limbs that is 
reflected in a degradation of the lower limb musculature (Pipinos, et al., 2008).  The 
repeated cycles of ischemia followed by reperfusion trigger inflammatory responses, 
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compromise cellular bioenergetics, and generate reactive oxygen species (Pipinos et al., 
2008).   
In this dissertation morphometric determinants, biochemical (mechanisms-based 
biomarker expressions), and spectral (Raman scattering) parameters of myofibers, in slide 
specimens of needle biopsies of the gastrocnemius, were used to characterize PAD 
muscle degeneration.  This contribution to PAD muscle degeneration research is 
significant because it may provide a basis for advances in both therapeutic intervention 
and improved monitoring of disease progression and clinical treatment interventions of 
PAD. 
 
6.1.1 Objective 1 – Morphometric analysis of PAD muscle  
This objective focused on characterizing the histology of PAD muscle with 
specific, quantifiable morphometric parameters of PAD and control myofibers.  A 
discriminant model, based on myofiber morphometrics, was developed and used to grade 
myofiber damage in the gastrocnemius of PAD patients.  In a small validation data set of 
28 patients, the model correctly classified CLI, claudicating, and control patients with 
88.8%, 77.7%, and 80.0% accuracies respectively, yielding an overall accuracy of 82.1%.   
Among the predictors, for the discriminant model, fiber density, variation of 
solidity, and roundness, had the most weight in the discriminant model.  Low fiber 
density reflects advanced injury characterized by fibrosis and deposition of adipose 
tissue.  This measurement quantifies the endomysial (in between myofibers) and 
perimysial (around myofascicles) thickening that occurs with increasing muscle damage.  
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Roundness appears to represent myofiber degeneration and/or necrosis associated with 
loss of sarcolemmal integrity and characterized by myofiber swelling.  
The discriminant scores, from this model, provided an index of disease severity in 
the patient limb musculature.  This grading index was a robust first step towards 
quantifying the progression of degeneration in the PAD leg. Claudicating patients with 
higher discriminant scores had more myofiber damage, similar to that of CLI patients.  
The higher the discriminant scores the higher the muscle degeneration.  This information 
may be used as a marker to identify and stage claudicating patients that may be prone to 
deteriorate to CLI. Clinicians may therefore consider more aggressive treatment for these 
patients.  Claudicating patients with lower discriminant scores had less myofiber damage 
and may be considered for different treatment.  Similarly, a grading index (coupled to 
clinical findings) may help clinicians choose the CLI patients that may be better served 
by revascularization, amputation or non-operative management. These findings will help 
advance the understanding of how the leg as end-organ is being damaged in PAD and 
quantify accurately and in a patient-specific manner the degree and type of degeneration 
in the PAD limb.   
6.1.2 Objective 2 – Oxidative damage and morphometric analysis of PAD 
muscle 
The goal of this objective was to quantify oxidatively altered proteins (hydrazide-
reactive carbonyls) with mechanisms-based molecular biomarkers and mathematically 
model disease progression based on a combination of morphometrics and oxidative 
damage.   PAD produces a progressive accumulation of ischemic injury to the limbs that 
is reflected in a gradual worsening in the microscopic morphology and oxidative stress in 
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the gastrocnemius (calf muscle).  This comprehensive discriminant model incorporated 
morphometric parameters of myofibers, oxidative damage in myofibers measured as 
protein carbonylation, measures of centrally located nuclei, and measures of clustering 
micro-fibers to create an improved discriminant model.  Biopsies were collected from the 
gastrocnemius with a Bergstom needle from PAD patients with claudication (n=19) and 
critical limb ischemia (CLI; n=20) and control patients (n=21).  The discriminant model, 
based on morphometric and oxidative stress parameters, was able to correctly classify 
clinical stages of PAD and control patients with an overall accuracy of 83.3% using a 
cross-validation procedure.  Myofiber morphometrics plus oxidative stress parameters 
provided a discriminant model that establishes a correlation between PAD progression 
and advancing muscle degeneration.  This model effectively separated PAD and control 
patients and provided a grading of muscle degeneration within clinical stages of PAD.  
6.1.3 Objective 3 – Raman spectral analysis of PAD muscle 
The work has demonstrated that surface enhanced Raman spectroscopy can be a 
powerful bioanalytical tool that is capable of detecting and correlating biochemical 
composition with patient ABIs and discriminating PAD clinical diagnosis.  Raman 
spectral biomarkers were identified and may be useful in complementing existing 
diagnosis and treatment monitoring methods of peripheral arterial disease (PAD).  
Muscle tissue biopsies of the gastrocnemius (calf muscle) were collected from 5 patients 
with clinically diagnosed critical limb ischemia (CLI), 5 patients with clinically 
diagnosed claudication, and 5 control patients who did not have PAD. A partial least 
squares regression (PLSR) model was developed and was able to predict patient ABIs 
with a correlation coefficient of 0.99 during training and a correlation coefficient of 0.85 
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using a full cross-validation.  When using the first three PLS factor scores in combination 
with linear discriminant analysis, the discriminant model was able to correctly classify 
the control, claudicating, and CLI patients with 100% accuracy, using a full cross 
validation procedure. This study demonstrated that Raman spectroscopy can be a 
powerful bioanalytical tool that is capable of detecting and correlating biochemical 
composition with patient ABIs and discriminating PAD clinical diagnosis.   Raman 
spectroscopy provides novel spectral biomarkers the may complement existing diagnosis 
and treatment monitoring methods of peripheral arterial disease (PAD).   
 
6.2 RECOMMENDATIONS FOR FUTURE RESEARCH  
 
Morphometric parameters, mechanisms-based molecular biomarkers of oxidative 
stress, and Raman spectroscopy analyses, of PAD muscle tissue showed promise as 
objective measures of muscle degeneration and methods for characterizing biochemical 
differences correlating to clinical stages of PAD.  Future research should be carried out 
with larger data sets to continue to validate and fine tune the models.  In addition, further 
development of multi-scale comprehensive models incorporating morphometrics, 
oxidative stress, Raman spectroscopy, and Fourier transform infrared spectroscopy may 
provide a more complete picture that more effectively models the biological phenomena.   
Fourier transform infrared spectroscopy (FTIR) is another powerful spectroscopic 
tool that is often useful for biochemical analytics.  Raman and FTIR spectroscopy both 
rely on vibrational energies of molecules for detection, but each method has different 
selection rules (Sasic and Ozaki, 2010).  In other words, molecules that produce Raman 
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spectral peaks generally will not appear in IR spectra and vice versa molecules that 
generate IR spectral peaks will not appear in Raman spectra.  These selection rules are 
useful because they make the two spectroscopic methods complementary to each other.  
Because FTIR and Raman spectroscopy are complementary the combination of these 
methods may provide a more complete biochemical profile of PAD muscle.  It would be 
very useful to combine these two complimentary techniques to further characterize 
biochemical alterations in PAD muscle tissue. 
Time resolved Raman spectroscopy may also prove to be a very useful analysis.   
Time series Raman spectra of freshly harvested muscle tissue incubated in an oxygen 
controlled chamber that cycles oxygen concentrations from resting to ischemic 
conditions, to simulate oxygen supply and demand in that occur in the body, may be very 
useful to examine in real time which Raman bands change shape. 
Raman spectroscopy can be further advantageous when it is coupled with imaging 
(i.e. mapping), which renders information rich Raman hyperspectral images.  Raman 
mapping is capable of identifying and constructing chemical maps of subcellular 
structures such as, the nucleus, cytoplasm, and mitochondria (Miljković et al., 2010; 
Bonnier et al., 2010).  Therefore, Raman spectral imaging (mapping) may be useful in 
providing insight into the biochemical spatial distribution of PAD myofibers and provide 
a visual of the biochemistry of PAD myofibers with respect to their neighboring 
myofibers.  Therefore, I recommend as a future aim to collect Raman spectral maps of 
PAD and control myofibers and evaluate the biochemical spatial distribution.  The 
successful completion of this future work may offer valuable insight as to where 
pathological changes occur within the muscle fibers.  This may be very useful to identify 
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group atrophy and provide insight as to how these pathological changes spread and affect 
neighboring muscle fibers.  For example, if a target legion is located and a cluster of 
fibers within a local neighborhood begin to become atrophic, these techniques may be 
able to examine biochemical changes occurring in the neighboring healthy muscle fibers. 
With high spatial and spectral resolution Raman mapping may prove to be a powerful 
technique for monitoring cellular physiology on a molecular level.  
As a long term goal I suggest the development of a Raman spectral probe that 
may be used minimally invasively.  A minimally invasive Raman spectral probe may 
useful in the detection of PAD muscle degeneration progression or regression in vivo and 
in situ, and may provide a great impact on disease management.   A minimally invasive 
Raman probe may be able to provide real time monitoring of muscle biochemistry during 
revascularization procedures or may be used to monitor progression or regression of 
PAD.   
 Further, the myofiber morphometric discriminant model showed promise in 
providing a grading index, to grade disease severity; however, one of the downfalls in 
this model is that it requires a biopsy from the patient.  The biopsy is minimally invasive; 
anytime we can get away from invasive procedures and in turn perform a noninvasive 
analysis the better.  Therefore, my suggestion is to further evaluate the potential of 
noninvasive imaging modalities that may be capable of capturing myofiber morphology 
in a noninvasive manner.  Noninvasive imaging techniques that can capture myofiber 
morphology offer the potential to improve patient specific diagnosis and improve 
treatment monitoring.    
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Among the potential imaging modalities that may be capable of measuring 
myofiber morphology in a noninvasive manner are micro-ultrasound and MRI.  A 
literature review article on ultrasound imaging and muscle limb function indicate that 
ultrasound imaging is capable of assessing components of muscle morphology (Walker et 
al., 2004).  However, ultrasound images are very noisy and at times may be hard to 
interpret.  Moreover, it may not be possible to image cross-sectional views of individual 
myofibers, although there are some literature reports that indicate high resolution micro-
ultrasound is able to resolve the micro-anatomy of myofibers (Walker et al., 2004; Van et 
al., 2009).  Despite these potential limitations, ultrasound may still be useful in collecting 
information that can be correlated to muscle damage.  
Physiological studies of patients with PAD indicate that there is a myopathy with 
mitochondrial dysfunction and oxidative damage to the muscle.  In addition to using 
protein carbonylation biomarkers, to measure oxidative stress, PAD injury could be more 
precisely quantified by incorporating more biomarkers.  Therefore, future research could 
also incorporate other biomarkers such as, 4-hydroxy-2-nonenal (HNE), which is 
produced during lipid peroxidation and appears in higher quantities during oxidative 
stress, ATP-synthase to measure for active mitochondria, ‘phosphatase and tensin 
homolog’ (PTEN) induced putative kinase 1 (PINK1) to stain for depolarized 
mitochondria, and signaling adaptor p62 to stain for ubiquitininated proteins that are 
marked for destruction. 
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CHAPTER 7 : APPENDICES: 
 
7.1 EXAMPLE MYOSIN AND SARCOLEMMA LABELING PROTOCOL USED 
IN CHAPTER 3 
Objective: Label myofiber myosin and sarcolemma for morphometric analysis of PAD 
and control gastrocnemius biopsies  
Rationale:   Preliminary work suggests that morphologic features of PAD myofibers may 
discriminate PAD and control specimens, and may correlate with disease severity.  
Design: 
 Slide specimens: 4 u sections of gastrocnemius biopsies from PAD patients and 
controls 
o Controls: 4 patients; H170, H171, H174 and H176 
o Claudicating patients: 4 patients; H168, H169, H175 and H180 
o Critical ischemia patients: 4 patients; H130, H135, H137 and H173 
 Deparaffinize slides with xylene 
 Hydrate slides to distilled water 
 Transfer slides to pre-heated epitope recovery solution 
 Set Pap pen windows  
 Apply goat serum 
 Incubate slides with a mixture of anti-Myosin I&II Abs (1hr) 
 Treat slides with Alexa Fluor 488 goat anti-mouse IgG (1hr) 
 Apply wheat germ agglutinin Alexa Fluor 350 (1hr) 
 Mount specimens in ProLong Gold and observe specimens with the Leica microscope 
 
Materials: 
 Slide specimens 
o Gastrocnemius biopsies 
o Specimens fixed in methacarn for 48 hours at 4o C 
o Transferred to 50% EtOH at 4o C 
o Paraffin embedded and sectioned at 4 u 
 AlexaFluor 350 conjugate wheat germ agglutinin, 1mg/ml: Molecular Probes           
cat # W11263, lot # 510811 
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 Anti-Type ‘1’ fiber: mouse monoclonal antibody; Sigma cat. # M8421, lot # 
115K4768, clone # NOQ7.5.4D; ascites fluid w/ 7.5 mg IgG/mL 
 Anti-Type ‘2 fiber: mouse monoclonal antibody; Sigma cat. # M4276, lot # 
026K4854, clone # MY-32; 7.8 mg IgG/ml 
 Alexa Fluor 488 conjugated goat anti-mouse IgG, 2mg/ml; Molecular Probes cat. # 
A11004,  lot # 745480 
 Antibody diluent: Zymed cat. # 00-3218, lot # 546892A, exp. 07-2010 
 Goat serum, 10%: Zymed cat. # 50-062Z, lot # 463107A, exp. 12-2009 
 Super Sensitive Wash Buffer: BioGenex HK583-5K, lot # HK5831208B 
 Tris: Invitrogen 15504-020, lot # 1140381 
 Dipotassium EDTA: Sigma ED2P, lot # 050K0247 
 Tween 20, Sigma cat. # P-7949, lot # 092K0051 
 Phosphate Buffered Saline, Invitrogen cat. # 14190, lot # 478900 
 Xylenes, Fisher cat. # X5P-1GAL, lot # 064546 
 Absolute EtOH, AAPER lot # 06H17WA 
 95% EtOH, General Supply, cat. # CP-3537 
 Methanol, EMD cat. # MX0475-1, lot # 43184328 
 Chloroform 
 Acetic acid, Fisher cat. # A38-212, lot # 053916 
 Hydrochloric Acid: Acros 423795000, lot # A0208645001 
 
Procedures: 
Prepare Tris buffer for epitope recovery 
 Tris base     1.45 g 
 Dipotassium EDTA   0.44 g 
 DdH2O     1200 mL 
 Adjust to pH 9.0 
 Tween 20     600 uL 
Deparaffinize and hydrate sections 
 Xylene, change ‘1’: 5 minutes w/ agitation 
 Xylene, change ‘2’: 5 minutes w/ agitation 
 Abs EtOH, change ‘1’: 3 minutes w/ agitation 
 Abs EtOH, change ‘2’: 3 minutes w/ agitation 
 95% EtOH: 1 minute w/ agitation 
 80% EtOH: 1 minute w/ agitation 
 DdH2O: 1 minute w/ agitation 
Epitope recovery  
 Transfer the slide to Tris buffer at 94o C 
 Keep at 94o to 98o C for 30 minutes 
 Allow the Tris with slides to cool on the bench for 20 minutes 
 Transfer the slides to Super Sensitive Wash Buffer at room temp for 30 minutes with 
a stir bar (setting of 2) 
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Place a lipid frame on each slide 
 Tap off water 
 Dry glass, except for tissue area 
 Add a drop of buffer to tissue sections (keep wet) 
 Draw frame to include middle 1/3 of slide 
 Add buffer to the tissue sections 
 Transfer slides to the BioGenex slide rack 
 
Prepare the anti-Type I Myosin (10.0 ug/ml) plus anti-Type II Myosin  (10.4 ug/ml) 
mixture 
 9000 ul of antibody diluent (50 cc conical tube) 
 12 ul of anti-Type I Myosin  
 12 uL of anti-Type II 
 
Prepare Agglutinin (10 ug/mL) plus secondary antibody (20 ug/mL) mixture  
 8000 uL of antibody diluent (50 cc conical) 
 Centrifuge the wheat germ agglutinin solution (100 uL) and Alexa 488 goat anti-
MIgG (100 uL) in the Fisher Microfuge at a setting of ‘10’ for 4 minute, room temp 
 Collect 80 ul of each supernatant 
 Dilute supernatants up to 8000 uL (antibody diluent)  
 
Run the AutoStainer program 
 Bring all solutions to room temperature 
 Bring the slides to room temperature 
 
Program the AutoStainer for the HNE/Carbonyl Slides 
    Duration Repeats  Final rinses 
 Prewash 
 Buffer     4 min  5   2 
 Buffer     4 min  3   2 
 10% goat serum  20 min  0   1 
 Anti-myosin mix  1.5 hour 0   2 
 Buffer     4 min  2   2 
 WGA/Anti-M IgG mix 1.0 hour 0   2 
 Buffer     4 min  2   2 
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Options: 
 Target middle 1/3 of each slide 
 Deliver 250 uL reagent 
 Inactivate the level sensor of the pipetting system 
 
Cover the tissue sections with ProLong Gold antifade medium 
 Avoid bubbles 
 Store slides at 5o C 
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7.2 EXAMPLE PROTEIN CARBONLY LABELING PROTOCOL USED IN 
CHAPTER 4. 
Objective: Evaluate the morphometric and carbonyl content of the PAD and control 
muscle and attempt to decrease the signal with borohydride reduction. 
 Rationale:   Oxidative stress results in the formation of protein carbonyls.  We will 
evaluate the PAD and control oxidative stress by biotin hydrazide labeling of carbonyl 
content. 
Design: 
 Three slides per subject  
o A (Negative (-) Myosin & Negative (-) Carbonyl) 
o B (Positive (+) Myosin & (+) Carbonyl) 
o C (Positive (+) Myosin & (+) Carbonyl)  
 Slide specimens prepared:  (total 12 humans) 
o Control Patient:  H217; H52;H51 
o PAD -Moderate:   H215; H108;  
o PAD- Severe:    H229; H162; H139; H178; H185; H186; H184; H108; 
o Carry Through: Control (H217) and MOD (H215) and  SEV (H229) 
(Day 1) 
 Deparaffinize slides with xylene 
 Hydrate slides to distilled water 
 Transfer slides to Citrate pH 6.0 solution for epitope recovery 
 Heat the slides at the microwave at 65°C for 10 min 
 Cool slides and transfer to supersensitive wash buffer 
 Set Pap pen windows 
 Extensive washing of the slides  
 Perform avidin/biotin block 
 Perform biotinylation 
 Stabilize hydrazine bonds with cyanoborohydride 
 Store with PBS on tissues in hydration chamber in refrigerator 
(Day 2) 
 Label with Streptavidin-AlexaFluor 488 (Carbonyl Labeling)  
 Wash the slides and apply goat serum block (Blocks non-specific binding sites) 
 Label (primary) with myosin mixture Anti-Type I/II Myosin  
 Label negative slides with Mouse IgG (Isotype Control) 
 Label (secondary) Alexa 594 Goat Anti-Mouse IgG (Myosin Labeling) 
 Label AlexaFluor 647 conjugate wheat germ agglutinin (Sarcolemma Labeling) 
 Mount specimens in ProLong Gold (with DAPI) and observe specimens with the 
Leica microscope 
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Materials: 
 Slide specimens 
o Gastroc  
o Specimen fixed in methacarn for 48 hours at 4o C 
o Transferred to 50% EtOH at 4o C 
 Avidin/Biotin Blocking Kit, Zymed ref. # 00-4303, lot # 911665A rec.06/21/11 
exp.8/12 
 Biotin Hydrazide: CALBIOCHEM, cat# 203110, lot# D00092953, rec. 8/27/11, exp. 
NA, MW: 484.66 
 Streptavidin-AlexaFluor 488: Molecular Probes S32354, lot # 748200 (2 mg/mL) rec. 
6-24-11 exp. N/A 
 10% Normal Goat Serum, Invitrogen lot# 899064A, ref# 50062Z,  rec 02/22/11, 
opened 04/08/11 
 Anti-Type ‘1’ fiber: mouse monoclonal anti-myosin (skeletal, slow); Sigma cat. # 
M8421-.2ML, lot # 011M4813, clone # NOQ7.5.4D; ascites fluid w/ (9.4 mg 
IgG/mL) 
 Anti-Type ‘2 fiber: mouse monoclonal anti-myosin (skeletal, fast); Sigma cat. # 
M4276-.2ML, lot # 059K4787, clone # MY-32; (8.5 mg IgG/ml) 
  Mouse IgG, Vector Laboratories Inc., lot#W0301, (2000 mg/1000mL), rec 07-06-10.  
  Alexa Fluor 594, goat anti-mouse IgG (H+L), Invitrogen Molecular Probes A11032,   
lot# 870954, (2mg/mL) rec. 6-24-11 exp. N/A 
 Alexa Fluor 647 conjugate wheat germ agglutinin, (1mg/ml): Molecular Probes           
cat # W11263, lot # 880275 rec. 2/22/11 exp. 9/11 
 Prolong Gold antifade reagent with DAPI, Invitrogen, P36931, lot # 838018 rec. 2/11 
exp. N/A 
 Antibody diluent: Invitrogen cat. # 00-3258, lot # 813641A, rec. 12/1/10 exp. 12/11 
 Super Sensitive Wash Buffer: BioGenex HK583-5K, lot # HK5830311 rec.6/21/11 
exp. 03/13 
 2-Morpholinoethane sulfonic acid (MES): Sigma, M3671-250G, lot # 020M5421 rec. 
8/25/10 exp. N/A, FW: 195.20 
 Phosphate Buffered Saline (PBS):  (made in lab) 
 Ethylenedieminetraacetic acid (EDTA): Invitrogen, ED2P, lot# 050K0247 
 Tween 20, Sigma cat. # P-7949, lot # 109K01021 rec. 3/1/10 exp. N/A 
 Xylenes, Fisher cat. # X5P-1GAL, lot # 084827 
 Absolute EtOH, AAPER lot # 06H17WA  
 95% EtOH, General Supply, cat. # CP-3537 
 Sodium Cyanoborohydride, 95%; Aldrich cat. # 156159-10G, lot # rec. 23/2/11 MW: 
62.84 
 Sodium Chloride, Fisher cat. # S271-1 rec. 06/05 exp. N/A MW: 58.44 
 Sodium Hydroxide, Fischer cat. # S318-500, lot # 034906 rec. 10/3 exp. N/A MW: 
40.00 
 Hydrochloric Acid: Acros 423795000, lot # A0208645001 
 Dimethylsulfoxide (DMSO), Sigma; cat. # 8418-250ML; lot # 845961MV rec. 
02/23/11 exp. N/A 
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Procedures: 
Day 1 
1. Prepare Citrate buffer  for epitope recovery Comments: 
 Tri-sodium citrate dihydrate 
 DdH2O   
29.4 g 
1000 mL 
 
 Adjust pH to 6.0  
 Tween 20    
 Store in refrigerator 
 
500 uL 
 
 
 
2. Prepare MES Buffer (Biotinylation Buffer) Comments: 
 200 mL 
 3.99 g MES to 200 mL DDW 
 Adjust the pH to 5.5, with concentrated NaOH 
Solution is good for 1 week 
Sample Calc: If we wanted to just prep. 
50ml 
 
3. Prepare 0.01 M Na Phosphate w/ 0.85% NaCl (PBS) Comments: 
 DdH20                                           1000mL 
 Na2HPO2                                        0.719 g 
 NaCl                                               4.2 g 
 Na2HPO4                                           0.69 g 
 NaCl                                                4.2 g 
 
To 400mL Dibasic, add Monobasic to pH 7.2 
(Makes 1 Liter) 
Fill 2 large beakers with 500 mL DdH20 
Add .719 g Dibasic & 4.2 g NaCl to 1 
beaker, Add 0.69 g Monobsic & 4.2 g NaCl 
to the other 
 
 
4. Prepare Super Sensitive Wash Buffer  Comments: 
 DdH2O                                        1900 mL 
 SS Buffer                                    100 mL 
(Makes 2 Liters) 
 
Deparaffinize and hydrate sections 
 Xylene, change ‘1’: 5 minutes w/ agitation 
 Xylene, change ‘2’: 5 minutes w/ agitation 
 Abs EtOH, change ‘1’: 3 minutes w/ agitation 
 Abs EtOH, change ‘2’: 3 minutes w/ agitation 
 95% EtOH: 1 minute w/ agitation 
 80% EtOH: 1 minute w/ agitation 
 DdH2O: 1 minute w/ agitation 
 
Epitope recovery 
 Transfer the slides to citrate buffer in the container of the microwave 
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 Set microwave to 65°C for 10 min 
 Allow solution with slides to cool in the fume hood for 20 minutes 
 Transfer the slides to Super Sensitive Wash Buffer at room temp with a stir bar 
(setting of 2) for 30 minutes 
 
Place a lipid frame on each slide 
 Tap off buffer 
 Dry glass, except for tissue area 
 Add a drop of buffer to tissue sections (keep wet) 
 Draw frame to include middle 1/3 of slide 
 Add SS buffer to the tissue sections to keep hydrated 
 Transfer slides to the BioGenex slide rack 
 
Program & Run the AutoStainer  
 Duration Repeats Final rinses Comments 
 Prewash     
 Buffer 
 Buffer 
4 min 
4 min 
5 
3 
2 
2 
(Super Sensitive Buffer) 
(Super Sensitive Buffer) 
 Avidin 10 min 0 2 (Bind to native biotin) 
 Buffer 4 min 2 2 (S.S. Buffer) 
 Biotin 10 min 0 2 (Binds to 4 sites in Avidin) 
 Buffer 4 min 2 2 (S.S. Buffer) 
 MES 5 min 0 0 (Biotinylation Buffer) 
Options: 
 Target middle 1/3 of each slide 
 Deliver 250 uL reagent (if 2/3 of slide increase to 500 uL) 
 Inactivate the level sensor of the pipetting system    
 
Prepare Biotinylation Solution  
(Step1) Prepare 50 mM Biotin Hydrazide 
DMSO Solution 
 Comments: 
 DMSO (on shelf) 100 ul  (get two vials 1st dissolve Biotin 
in DMSO then add that solution 
to MES if crystals form 
―sonicate. 
(reacts with aldehydes & 
keytones & forms hydrozone 
bonds) 
 Biotin Hydrazide (in 
refrigerator) 
2.5 mg 
   
(Step2) 
Prepare 
Immediately 
prior to use 
Prepare 5 µM Biotinylation 
Solution 
 
 50 mM Biotin DMSO 
 (from step1) 
100 ul  
(stirred in warm water) 
(Yields 1 mL)  MES Buffer 900 ul 
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Biotinylation 
 Add 400 ul of Biotinylation solution to each slide 
 Incubate at room temperature for 1 hr in flat black slide box (fill bottom of box 
with plenty of DdH2O) 
 Wash slides with PBS in glass container with stir bar (setting 2) for 10 min. 
 
   
Prepare 15 mM Cyanoborohydride   
Comments: 
 PBS (in refrigerator) 250 ml 
(Mix under the Hood) 
(Yields 1 glass containers worth)  Sodium cyanoborohydride  
(in vacuum under the hood) 
0.24 g 
 
 
Stabilize the hydrazone bonds with cyanoborohydride  
 Tap off the biotinylation solution 
 Place slides in 250 ul of 15 mM cyanoborohydride in glass container 
 Incubate at room temperature with stir bar (setting 2) for 30 minutes 
 
Prepare for overnight incubation 
 Fill flat black slide boxes with DdH20 (enough to fully coat the bottom) 
 Dip each slide in PBS several times to wash 
 Place slides in slide box and flood windows with PBS 
 Store overnight in refrigerator 
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Day 2  Procedures: 
Prepare the Streptavidin-Alexa 488 (10 ug/ml): 
 Centrifuge the streptavidin in the Fisher Microfuge at a setting of ‘10’ for 4 minute 
 17.5 ul of Streptavidin  (put back in refrigerator when done) 
 3500 uL Ab Diluent  (1:200) 
 
Prepare the mixture Anti-Type I/II Myosin (10 ug/ml) 
 2000 uL of antibody diluent  
 2.5 uL of Anti-Type I (slow) Myosin (1:940) 
 2.5 uL of Anti-Type II (fast) Myosin (1:850) 
 
Prepare the Mouse IgG (Isotype Control) (5 ug/ml): 
 Centrifuge the mouse IgG in the Fisher Microfuge at a setting of ‘10’ for 4 minutes 
 2 uL of Mouse IgG  
 5000 uL Ab Diluent  (1:400)  
 
Prepare the Alexa 594 Goat Anti-Mouse IgG (10 ug/ml): 
 Centrifuge the Alexa fluor in the Fisher Microfuge at a setting of ‘10’ for 4 minute 
 20 uL of Alexa 594 
 4000 uL Ab Diluent  (1:200) 
 
Prepare Agglutinin Alexa 647 (1:100) 
 Centrifuge the wheat germ agglutinin solution in the Fisher Microfuge at a setting of 
‘10’ for 4 minute 
 Add  50 uL of the supernatant  
 2500 uL of Ab Diluent (1:50)  
 Notes: Vortex wheat germ agglutinin rigorous 3 times before use 
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AutoStainer 
Program the AutoStainer  
     Duration Repeats  Final rinses 
 Pre-wash 
 Buffer     4 min  2   2 
 Streptavidin 488  30 min  0   0 
 Buffer     4 min  2   2 
 Goat Serum  20 min  0   1 
 Myosin Mixture  90 min  0   0 
 Isotype Control  90 min  0   0 
 Buffer     4 min  2   2 
 Alexa 594    30 min  0   0 
 Buffer     4 min  2   2 
 Agglutinin   60 min  0   0 
 Buffer    4 min  2   2 
 
Options: 
 Target middle 1/3 of slides 
 Deliver 250 uL reagent per slide 
 Inactivate the level sensor of the pipetting system 
 
Runs the autostainer 
 
Mount the slides with ProLong Gold Anti-fade medium with DAPI 
 30 uL for each slide 
 
Store at room temp in slide folder 
 
 
Observe the slide specimens with the Leica system 
 
 
 
 
 
 
 
